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Abstract  
 
The work in this thesis applies magnetization transfer imaging (MTI) and 
conventional MRI measures (brain volume, T2 lesion load and enhancing lesions) 
to investigate the mechanisms underlying progression in primary progressive 
multiple sclerosis (PPMS), and identifies MR markers to predict and monitor 
progression. 
 
First, we demonstrated that MTI was sensitive to change in the normal appearing 
brain tissues over one year, and that clinical progression over this period was 
predicted by baseline normal appearing white matter (NAWM) MT ratio (MTR). 
However, our second study showed that over three years, grey matter MTR 
became a better predictor of progression than any other MRI measure. Grey matter 
MTR and T2 lesion load changes reflected concurrent progression during this 
study. 
To localize the baseline grey matter injury more precisely, we developed a voxel-
based technique to identify areas of grey matter MTR reduction and volume loss in 
patients compared with controls. The regions of grey matter MTR reduction 
identified correlated with clinical function in anatomically related systems.   
 
Finally, because our studies showed that lesion load influenced progression, we 
used contrast enhanced T1-weighted imaging to examine active focal 
inflammation. We found that while lesion activity declined over five years, levels of 
activity at the start of the study could influence mobility five years later.  
 
The work presented in this thesis suggests that grey matter damage has a 
predilection for certain brain regions and is an important determinant of 
progression in early PPMS. In the white matter, changes in lesion volume and 
activity continue to influence progression, but NAWM injury may have a declining 
role. MTR is a sensitive and responsive tool for predicting, monitoring, and 
localizing clinically relevant brain injury in early PPMS.  Understanding progression in PPMS     4 
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The chapter begins with an overview of the clinical features of primary progressive 
multiple sclerosis (PPMS), and current knowledge of the pathological processes 
underlying it. In contrast to other MS subtypes, no disease modifying treatments 
are available for PPMS, and the particular challenges for clinical trials in this group 
are outlined. The second half of the chapter explores the application and limitations 
of MRI for investigating the disease process in PPMS, summarizing research 
findings to date.  
 
1.1 Primary progressive Multiple Sclerosis 
 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system, and it is the commonest cause of neurological disability in young adults in 
the UK. Patients typically follow a relapsing-remitting disease course (RRMS), 
presenting with acute neurological dysfunction (a relapse) followed by some 
degree of recovery and a period of indefinite remission, before further relapses. 
After some years a proportion of patients show a gradual functional deterioration, 
independent of relapse activity, which is called secondary progression (Lublin 
1996). A minority of patients with MS progress from onset without relapses, and 
are described as having primary progressive MS (PPMS).  
 
1.1.1  Epidemiology 
 
MS has a prevalence of 97-184/100 000 (Pugliatti 2006), and an incidence of 
5.5/100 000 (Alonso 2007) in the UK. Northern European populations are 
particularly affected, and incidence remains higher in these groups in North 
America, Canada and Australia (Ebers 2008). However, MS has been diagnosed 
worldwide (Cheng 2007, Alter 2006, Cabre 2001, Kantarci 1998). 
  
Detailed information regarding PPMS is more difficult to collect, but three 
epidemiological reports from Asia (Yamout 2008, Maghzi 2007, Wasay 2007) and 
one from Africa (Modi 2008) specifically mention PPMS. In a European 
epidemiological review, estimates of PPMS prevalence ranged from 4 to 35% of all 
MS cases (Pugliatti 2006). This probably reflects the difficulty of categorizing                                                          Understanding progression in PPMS: Introduction     20 
patients before definitive diagnostic criteria were set out in 2000 (Thompson 2000). 
It is generally accepted, from natural history studies in MS cohorts, that PPMS 
constitutes 10-15% of all MS cases (Tremlett 2005, Thompson 2004, Confavreux 
2000, Runmarker 1993). In contrast to RRMS, where there is a female 
preponderence, PPMS has an equal sex distribution. The age of onset is usually in 
the fourth or fifth decade (Tremlett 2005, Cottrell 1999), roughly ten years later 
than in RRMS (Compston 2002); similar to the onset of secondary progression 
(Confavreux 2006b, Ebers 2004). PPMS in children is extremely unusual, but has 
been described (Renoux 2007, Boiko 2002).  
 
1.1.2 Aetiology  
 
Genetic susceptibility to PPMS has been mapped to the same region as RRMS: 
the HLA class II region of the MHC molecule on the short arm of chromosome 6, 
specifically the HLA-DR2 allele DRB1*1501. HLA alleles do not appear to influence 
the age of onset or severity of the disease (Barcellos 2006). More recently, single 
nucleotide polymorphisms at IL7R and IL2R have been implicated in MS 
susceptibility, in large scale genome-wide association studies, which have included 
patients with PPMS (Hafler 2007). Australian studies postulate that there is under-
expression of the IL7R alpha chain mRNA, CD127, in PPMS in particular, and that 
this affects the T cell response (McKay 2008). Thus there are some indications that 
genetic factors may have some influence on disease subtype. Another study in 
1083 families with MS suggested a slight concordance for a primary progressive 
clinical course among siblings (kappa<0.2); however, concordance was not 
observed among parent-child groups (Hensiek 2007). A French study recently 
found that the DRB1*15 allele was more frequent in patients developing SPMS, 
compared to both PPMS patients and RRMS patients who had not converted after 
12-15 years (Cournu-Rebeix 2008).  
 
The recurrence rate in monozygotic twins for all types of MS taken together is just 
over one third (Ebers 2008), suggesting that environmental factors also play a role 
in disease causation. This phenomenon can not be identified at an individual level, 
but can be seen in large cohorts at a population level (Sawcer 2008). Although                                                          Understanding progression in PPMS: Introduction     21 
there is no specific data for PPMS, studies in genetically homogenous populations 
suggest that MS incidence increases with latitude (Vukusic 2007), although this 
pattern appears increasingly complex and could be changing (Ascherio 2007). For 
example, east-west geographic variations also exist, with some irregularity, and 
countries at the same latitude do not all have the same incidence (Ebers 2008). 
Migration studies also provide evidence of a complex environmental influence. 
While child migrants take on the risk profile of their host community, those who 
migrate later in life maintain the risk associated with their country of origin (Dean 
1997). Similarly, second generation African and Asian immigrants have a higher 
risk than their parents (Elian 1990). Furthermore, the specific environmental agents 
which trigger MS in susceptible individuals remain unidentified. One hypothesis 
centres on sunlight exposure, which varies with latitude and is the principal inducer 
of vitamin D production: studies have suggested that vitamin D is an immune 
modulator (Smolders 2008), and that higher vitamin D levels protect against MS 
(Munger 2006). Diet may be another significant element in modulating individual 
responses to other risk factors (Ebers 2008). Finally, a large number of infectious 
agents, particularly viruses, have been implicated in MS, although no causal 
association has been proved. The strongest candidate at present is the Epstein-
Barr virus (EBV). Almost all patients with MS are sero-positive for EBV, compared 
to 90% in the general population (Giovannoni 2007).  
 
Regarding PPMS in particular, there is little information available on specific 
environmental risk factors. Smoking may be a risk factor for PPMS (Hernan 2005), 
although it has no effect on age of onset or disability accrual (Koch 2007). While 
there is evidence that Spring births increase the risk of RRMS (Willer 2005), timing 
of birth does not seem to influence PPMS susceptibility (Sadovnick 2007). A recent 
study suggests that the immune response to EBV may be related to disease 
subtype (Farrell 2009), but it remains to be established whether this is a cause or a 
consequence of phenotypic differences.                                                           Understanding progression in PPMS: Introduction     22 
 
1.1.2  Symptoms, Signs and Clinical Course  
 
The clinical onset of PPMS tends to be insidious, with a gradual functional 
deterioration over months and years. While symptoms may fluctuate through the 
year, and sometimes remain stable for long periods, accumulated disability is 
irreversible. The majority of patients present with a progressive spinal cord 
syndrome, usually leg weakness and stiffness progressing to spasms. Initially, 
weakness may be evident only after exercise, and is often asymmetrical. Urinary 
urgency and constipation are common, and erectile dysfunction may be a feature. 
More rarely sphincter disturbance manifests as faecal urgency. Sensory 
symptoms, though less prominent than in RRMS, may be distressing and include 
pins and needles, numbness and pain. Less commonly, patients present with poor 
balance and tremor or hemiplegia, and very rarely with progressive visual or 
cognitive decline. Examination may reveal a spastic para- or hemi-paresis, 
cerebellar signs, and sensory loss which tends to be patchy rather than describing 
a definite sensory level.  
 
Cognitive impairment occurs in all MS subtypes. A study in 24 PPMS patients, with 
a mean disease duration of 5.4 years, emphasized information processing speed 
as the most markedly affected domain in comparison to healthy controls, and the 
only domain markedly declining over 3 years. Verbal memory was also impaired, 
and age had a significant impact on performance (Denney 2008). A larger group of 
99 PPMS patients with more advanced disease demonstrated wide heterogeneity 
in cognitive decline over two years; roughly one third deteriorated on individual 
tests (Camp 2005). Several studies have compared cognitive decline in PP and 
SPMS (Bergendal 2007, Wachowius 2005, Foong 1997, Comi 1995). There is no 
consensus as to which subtype, matched for age and disease duration, shows 
greater cognitive impairment, and while some studies indicate qualitative 
differences between the impaired domains (Kraus 2005, Gaudino 2001), others do 
not (de Sonneville 2002). It is possible that wide variations within subtypes (Kraus 
2005) have made differences harder to detect in these studies, all of which are 
limited in cohort size.                                                           Understanding progression in PPMS: Introduction     23 
 
Gradual progression of the presenting syndrome is typical. In severe cases 
paraparesis progresses to quadriparesis, cerebellar involvement and, at an 
advanced stage, brainstem dysfunction with dysphagia and dysarthria.  
The rate and character of progression is broadly similar to the secondary 
progressive phase in patients with RRMS (Kremenchutzky 2006, Confavreux 
2006a, Confavreux 2000). Indeed, in secondary progressive MS the previous 
relapse history appears to have minimal influence on eventual disability (Ebers 
2004, Confavreux 2003, Confavreux 2000).  
 
However, the rate of disability accrual varies widely between individuals in PPMS. 
In a large natural history study from Canada, 25% of patients required a walking 
aid seven years after onset, but 25% were still walking independently at twenty-five 
years (Tremlett 2005). The mean time to reach EDSS 6 (the patient requires a 
cane to walk) was 13.3 years. Studies in other cohorts have identified a worse 
prognosis, ranging from 6 to 8.5 years (Confavreux 2000, Cottrell 1999, Andersson 
1999, Runmarker 1993).  
 
At present, clinical indicators of future prognosis are uncertain. In the London, 
Ontario cohort, the small number of patients presenting with involvement of more 
than three systems had a worse prognosis (Cottrell 1999). A study from British 
Columbia indicated that involvement of the brainstem and cerebellum at 
presentation may adversely affect prognosis, and these symptoms were more 
common in men (Tremlett 2005). Both the London Ontario and Lyons cohorts 
describe a poorer prognosis in men (Confavreux 2006a, Cottrell 1999), but this is 
not a feature of all studies (Andersson 1999). Finally, both the Canadian studies 
suggest that the rate of initial progression is an important indicator of future 
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1.1.4 Pathology  
 
1.1.4.1 White matter plaques  
The MS plaque is an area of demyelination, axonal loss and oligodendrocyte death 
on a background of inflammation (Bruck 2002). Plaques typically occur in the white 
matter, but are also abundant in grey matter (Peterson 2001). They are thought to 
result from a breach in the blood brain barrier, which allows the infiltration of 
macrophages, T cells and plasma cells into the central nervous system, and 
activates resident microglia (Frohman 2006). The inflammatory T cells attack 
myelin and oligodendrocytes in the central nervous system, creating a focus of 
inflammatory activity (Frohman 2006). Gradually, inflammation gives way to 
fibrillary gliosis, with fewer macrophages, loss of oligodendrocytes, and a decrease 
in axonal density, particularly at the lesion centre (Lucchinetti 2004).  
 
Post mortem investigations have demonstrated fewer inflammatory cells in PP 
compared to SPMS lesions (Revesz 1994), and specifically a reduction in T cells 
and macrophages has been described (Lucchinetti 2004). Magliozzi and 
colleagues found less meningeal inflammation in PP compared to SPMS, with 
fewer B cells seen in perivascular cuffs. The ectopic B cell meningeal follicles 
which they identified in SPMS, which may have produced a locally sustained B cell 
inflammatory response, were absent in PPMS (Magliozzi 2007). Finally, both PP 
and SPMS plaques tend to demonstrate a tendency to slow radial expansion, with 
a lower percentage of classical active lesions, when compared to RRMS 
(Kutzelnigg 2005, Prineas 2001).  
 
Some investigators have postulated inter-patient lesion heterogeneity in MS, with 
intra-patient homogeneity. Four lesion types with different mechanisms of myelin 
injury were identified, and pattern IV, demonstrating oligodendrocyte dystrophy 
without remyelination, was found exclusively in PPMS (Lucchinetti 2000). However, 
this concept was challenged in 2004 (Barnett 2004), and more recently another 
study found acute lesions to be homogeneous, and oligodendrocyte apoptosis to 
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1.1.4.2 Diffuse white matter pathology 
The relevance of white matter pathology outside defined plaques has been 
increasingly recognized over the last two decades (Trapp 1999). Damage to the 
healthy-appearing white matter is most pronounced in progressive MS (see Figure 
1a), and involves widespread reduction in myelin and axon density on a 
background of parenchymal, perivascular and meningeal inflammation. 
Inflammation is less marked in PP compared to SPMS cases (Kutzelnigg 2005). 
The relatively normal appearance of the white matter may be preserved by the 
persistence of some myelin sheaths despite Wallerian degeneration of associated 
axons secondary to transection in lesions (Dutta 2007). There is no obvious 
correlation between NAWM injury and white matter lesion load, suggesting that 
diffuse white matter injury may be independent of lesion pathology (Kutzelnigg 
2005). 
    
 
Figure 1a: Diffuse white matter injury in 
the brain in PPMS  
 
Only the subcortical myelin is intact, and there 
are few focal demyelinated plaques 
Luxol fast blue stain, x0.5 
 
 
(adapted from Kutzelnigg et al, Brain 2005) 
 
 
 
1.1.4.3 Grey matter pathology 
Although grey matter demyelination was identified in the nineteenth century, it is  
only recently that its true extent has been appreciated. This is partly because the 
conventional lipid stains, used in the past for histo-pathological studies, were not 
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immunohistochemical techniques, have shown that lesions in the cortex and deep 
grey matter are prominent in progressive MS (Kutzelnigg 2007) and three types of 
cortical lesion have been identified (Peterson 2001): leukocortical lesions (type I), 
small cortical lesions, often perivascular (type II), and the commonest type, subpial 
lesions which can extend into layers III and IV of the cortex (type III). There are 
fewer inflammatory cells in grey matter lesions compared to white matter lesions 
(Pirko 2007, Peterson 2001), and marked neuro-axonal injury and neuronal 
apoptosis have been identified (Dutta 2007, Kutzelnigg 2005, Peterson 2001). 
Some neuronal damage may be ascribed to Wallerian and retrograde degeneration 
following white matter axonal injury, but the lack of association between focal white 
matter and grey matter injury suggest that the latter is a largely independent 
process (Lassmann 2007, Bo 2007). Extensive grey matter demyelination has also 
been demonstrated in the spinal cord, in patients with progressive MS (Gilmore 
2006). 
 
1.1.4.4 Remyelination  
There is evidence that some lesions seek to repair themselves. Oligodendrocyte 
numbers are increased in such lesions, known as shadow plaques, and myelin 
density is intermediate between fully demyelinated lesions and healthy brain tissue. 
Remyelination occurs in all MS subtypes (Patrikios 2006), does not diminish with 
disease duration (Patani 2007), and appears to be most extensive in the cortex 
(Albert 2007). In the white matter, remyelination is more often seen in deep and 
subcortical compared to periventricular lesions (Patrikios 2006). 
 
In summary, the pathology of progressive MS is distinct from RRMS in the relative 
preponderance of injury to the grey and NAWM. The pathology of PPMS is distinct 
from RRMS in the relative paucity of active focal inflammation, and from SPMS in 
the relative reduction of diffuse and focal inflammation. 
 
1.1.5 Diagnosis  
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on evidence of dissemination in time and space were formalized by the Poser 
Committee in 1983 (Poser 1983), and for the first time evoked potential or MRI 
evidence of a second lesion was accepted in lieu of clinical evidence. To achieve a 
laboratory supported diagnosis, it was necessary to demonstrate intrathecal 
synthesis of IgG on CSF analysis. However, these criteria were inappropriate for 
PPMS, by definition a slowly evolving deficit, often in a single system. This was 
addressed by Thompson in 2000 (Thompson 2000) who established three levels of 
diagnostic certainty (definite, probable and possible). The criteria were based on 
clinical information and supportive investigations (CSF, MRI, VEPs), for application 
to patients who had progressed for one year and in whom alternative diagnoses 
had been appropriately excluded. The identification of intrathecal IgG synthesis 
was mandatory for a definite diagnosis. These criteria were largely adopted in the 
international diagnostic criteria for MS in 2001 (McDonald 2001). In 2005, the 
criteria were simplified (Polman 2005), and, in the light of evidence put forward 
from the PROMiSe trial (Wolinsky 2003), a positive CSF analysis is no longer 
essential for diagnosis (see Table 1.A).  
 
1.1.6 Investigations  
 
MRI of both the brain and spinal cord is recommended, as the majority of patients 
present with a spastic paraparesis, and because lesions in the spinal cord may, 
rarely, be present in the absence of brain lesions (Thorpe 1996). In addition, age-
related non-specific white matter lesions are rare in the spinal cord, and therefore 
lesions identified at this site are more suggestive of MS (Kidd 1993). CSF analysis 
reveals increased intrathecal synthesis of IgG or the presence of oligoclonal IgG 
bands which are absent in the serum, in about 80% of PPMS cases (Wolinsky 
2004, Andersson 1999). Visual evoked potentials demonstrating a preserved 
waveform with a prolonged P100 latency can be taken as evidence of 
demyelination in the optic nerve (Thompson 2000). However, symptomatic optic 
neuritis is unusual in PPMS, and there is little data regarding the frequency of VEP 
abnormalities in this group. In a small study including 14 patients with PPMS it was 
suggested that VEP abnormalities may be less common than in SPMS, but of                                                          Understanding progression in PPMS: Introduction     28 
similar frequency to RRMS (Rot 2006). Motor and somatosensory evoked 
potentials may also be delayed in PPMS. 
 
Table 1.A Diagnosis of PPMS  
 
Original McDonald Criteria  2005 Revisions 
1. Positive CSF and  1. One year of disease progression 
(retrospectively or prospectively determined) 
2. Dissemination in space by MRI 
evidence of nine or more T2 brain 
lesions or 
2. Plus two of the following: 
 
a.  Positive brain MRI (nine T2 lesions or  
   four or more T2 lesions with positive VEP) 
 
   b. Positive spinal cord MRI (two focal T2  
   lesions) 
 
   c. Positive CSF (isoelectric focusing  
   evidence of oligoclonal IgG bands or  
   increased IgG index or both). 
     Two or more cord lesions or 
      Four to eight brain lesions and one  
      cord lesion or 
      Positive VEP with four to eight MRI  
      lesions or 
      Positive VEP with less than four  
      brain lesions plus one cord lesion 
      and 
3. Dissemination in time by MRI or 
Continued progression for 1 year 
 
(taken from Polman et al, Annals of Neurology 2005) 
 
1.1.7 The role of disease modifying treatments 
 
The disease modifying treatments used in RRMS are anti-inflammatory drugs 
which target relapses. The inflammatory component of PPMS implies a potential to 
respond to these treatments. The studies which have investigated this possibility 
are discussed in the next part of this section. However, disease modifying agents 
have proven largely ineffective in PPMS. Management has therefore focused on 
symptomatic control and rehabilitation (Jenkins 2008), with the hope that future 
treatment strategies aimed at neuro-axonal protection and repair will be more 
productive (Leary 2005).  
 
The largest randomized study in PPMS is the PROMiSe trial of glatiramer acetate, 
in which 943 patients with PPMS were randomised to placebo or glatiramer acetate 
for 3 years. Unfortunately, a lack of progression in both arms studied made it                                                          Understanding progression in PPMS: Introduction     29 
impossible to identify a treatment effect, and the study was terminated early 
(Wolinsky 2007) . Beta interferons are widely used to treat RRMS and SPMS with 
relapses, and two small placebo controlled trials have been performed in PPMS. 
The first, on interferon beta-1a, found no reduction in disability accumulation, brain 
or spinal cord atrophy (Leary 2003). However, patients on the drug had a lower 
rate of T2 lesion accumulation. In the second study, testing interferon 1-beta 
versus placebo in 73 patients, a favourable effect was demonstrated on the MSFC 
in the treated group. T2 lesion load accumulation was reduced, although brain and 
spinal cord atrophy were not (Montalban 2004). Mitoxantrone has been studied in a 
small placebo controlled trial in 61 patients with PPMS (Stuve 2004), but 
preliminary results have not been positive (Miller 2007). Further, retrospective 
analysis of 163 patients with PPMS showed that those taking mitoxantrone 
continued to progress (Debouverie 2007). A randomised control trial investigating 
monthly intravenous immunoglobulin infusions suggested that progression was 
delayed in eight patients with PPMS, though there was no significant effect in the 
much larger group of SPMS patients (Pohlau 2007). A randomised controlled study 
of the monoclonal antibody Rituximab is underway (Miller 2007) following a report 
of successful B cell depletion in patients with PPMS (Monson 2005). Open label 
studies in perfenidone, an immune modulating oral medication (Bowen 2003), and 
cyclophosphamide (Zephir 2004) have appeared to demonstrate stabilization of 
PPMS patients, but interpretation is limited by study design. Studies in 
methotrexate (Goodkin 1995), azathioprine (British and Dutch Multiple Sclerosis 
Azathioprine Trial Group1988) and cladribine (Rice 2000) have included PPMS, 
but no benefit was demonstrated. A retrospective study of haematopoetic stem cell 
transplantation reported benefit in a proportion of PPMS patients, but mortality was 
considerable (Fassas 2002).  
 
From the point of view of neuro-protection, riluzole has shown some promise in 
preliminary studies (Kalkers 2002), and an unblinded pilot study in high dose 
recombinant erythropoetin showed some improvement in motor function over 24 
weeks (Ehrenreich 2007). Intravenous methylprednisolone, used in RRMS to 
shorten relapse duration, may sometimes be used for subacute functional 
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investigate steroids as neuro-protective agents in progressive MS, following 
retrospective reports of longer term clinical benefit (Pirko 2004). 
 
Many of these studies highlight the difficulties of performing clinical trials in PPMS. 
Firstly, PPMS is a relatively uncommon MS subtype, which limits cohort sizes. This 
can only be addressed by large multi-centre collaborations. Secondly, in the 
absence of prognostic markers for progression, recruitment is unselected. Thus 
some study patients may progress very gradually, making treatment effects difficult 
to identify over short periods of time. Finally, while MRI outcome measures such as 
T2 lesion load have responded to treatment in some studies, the uncertain 
relationship between these measures and disease progression in PPMS makes the 
findings difficult to interpret. For this reason reliable, responsive surrogate outcome 
measures, which accurately reflect concurrent and future clinical progression, are 
needed to facilitate clinical trials in PPMS. MRI studies have tried to address some 
of these issues, and are discussed in the next section as part of a brief overview of 
MRI in PPMS.  
 
1.2 Imaging and PPMS 
 
1.2.1 Conventional MRI measures 
 
1.2.1.2 T2 and T1 lesions 
White matter plaques are best visualized on proton density-, T2-weighted and fluid 
attenuated inversion recovery (FLAIR) imaging. Lesions are usually less than 1cm 
in diameter and rounded in shape, but adjacent lesions may coalesce. 
T2 lesions are pathologically heterogeneous, showing wide variations in levels of 
demyelination, inflammatory activity and axonal loss (Fisher 2007). In PPMS, 
lesions are fewer and smaller than in other MS subtypes (Thompson 1990), and 
increases in T2 lesion load are largely due to expansion of existing lesions rather 
than to the formation of new ones (Stevenson 2000). Recent work suggests that 
the smaller T2 lesions occurring in PPMS are more persistent and destructive than 
larger lesions in RRMS (Meier 2007). This may contribute to the poor correlation 
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tend not to be visible on T2-weighted images. They have a signal intensity close to 
the normal grey matter, and are rarely seen on MRI even at higher field strengths 
(Geurts 2008). This may further limit the ability of T2 lesion loads to reflect the 
disease burden in PPMS.  
 
T2 lesions which develop into areas of hypo-intensity on T1-weighted images are 
called 'T1 black holes'. In progressive MS a greater proportion of T2 lesions 
develop in this way compared to RRMS (Wolinsky 2004, van Walderveen 2001). 
Some of the black holes persist indefinitely, representing focal areas of irreversible 
matrix destruction and axonal loss (van Walderveen 1998). There is some 
indication that T1 lesion load correlates better than T2 with disability in SPMS 
(Truyen 1996), but this has not been demonstrated in PPMS. 
 
1.2.1.2 Gadolinium enhancing lesions 
It is not possible to demonstrate the age or activity of a lesion on unprocessed 
unenhanced T1 and T2 imaging. Gadolinium, an intravenous contrast agent, 
penetrates the blood brain barrier in areas of active inflammation causing 
enhancement of active lesions on T1-weighted images (Bruck 1997). While the 
majority of T2 lesions show some gadolinium enhancement, a minority do not; it 
has been suggested that these lesions, which are often peri-ventricular, may arise 
from mechanisms other than BBB breakdown, such as Wallerian degeneration or 
the coalescence of two smaller lesions (Lee 1999). Lesions may enhance uniformly 
or inhomogenously. Some demonstrate ring enhancement, possibly representing 
the concentric pattern of lesion recovery (Meier 2007). Lesions which have ceased 
to enhance may reactivate and start to enhance again (Bruck 1997). Enhancement 
continues for a variable amount of time, but usually lasts less than 2 months 
(Ciccarelli 1999), and there have been suggestions that lesions which enhance for 
longer are more destructive (Silver 1999). Enhancing lesions may develop into T1 
black holes, remain as T2 hyper-intensities, or resolve completely, and this varies 
both between subjects and in different lesions within a subject (Minneboo 2005, 
Ciccarelli 1999).  
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on MRI compared to SPMS (Thompson 1991); only 14% of the PPMS patients 
entering the PROMiSe trial had gadolinium enhancing lesions (Wolinsky 2004). 
However, a study in patients with early PPMS have demonstrated a higher  level of 
gadolinium enhancement, albeit using triple dose gadolinium (Ingle 2005), 
suggesting the possibility of an early inflammatory phase. This may have 
implications for the potential of anti-inflammatory disease modifying therapies 
during the early stages of PPMS. 
 
1.2.1.3 Brain Atrophy 
Atrophy is a putative marker for axonal loss, but other pathological processes 
affect tissue volume including gliosis, axonal swelling, inflammation, and 
demyelination (Fisher 2007, Kezele 2007, Simon 2006). In addition, the temporal 
relationship between loss of axons and subsequent volume loss is not clearly 
established (Simon 2006). Brain volume has been correlated with clinical function 
in cross-sectional studies in established PPMS (Nijeholt 1998). In longitudinal 
studies, atrophy does not correlate with accumulation of disability in the short term 
(Ingle 2002, Stevenson 2000), but an association is evident over five years (Ingle 
2003b). Brain atrophy on an initial scan can also predict long term clinical outcome 
(Sastre-Garriga 2005b, Ingle 2003a). In early PPMS, atrophy is already present in 
both grey and NAWM, and a correlation between NAWM volume and clinical 
function has been identified (Sastre-Garriga 2004). 
 
1.2.1.4 Spinal cord imaging 
Spinal cord lesions are less likely than brain lesions to demonstrate enhancement, 
or to develop into T1 lesions (Neema 2007). In PPMS, there are fewer lesions in 
the spinal cord, with less enhancement, than in other MS subtypes. In addition, a 
diffuse T2-weighted signal abnormality, shown to represent demyelination on 
histological studies (Bergers 2002), may be visible in PPMS. Spinal cord lesions 
have not shown strong correlations with disability in PPMS (Nijeholt 1998). Spinal 
cord volume is reduced in PPMS, although not as much as it is in SPMS. 
Compared with brain imaging parameters, spinal cord atrophy was found to be the 
best way of separating early PPMS and early RRMS (Bieniek 2006).  Cord atrophy 
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with clinical measures in cross-sectional studies in PPMS (Stevenson 1998) , and 
loss of cord volume over two years has been correlated with disability accrual over 
five years (Ingle 2003b).  
 
Figure 1b: Brain and spinal cord atrophy in two patients with PPMS 
T1-weighted FSPGR sequences showing marked volume loss in the brain and spinal cord 
 
       
 
1.2.1.5 The Clinico-radiological Paradox 
The relationship between abnormalities identified on conventional imaging and 
disability has been surprisingly limited (Barkhof 2002), particularly in PPMS 
(Stevenson 1999). Longitudinally, the modest correlation between changes in 
clinical and MR measures may become apparent only after several years (Ingle 
2003b, Ingle 2002). A number of explanations for this have been suggested. 
Firstly, clinical outcome measures used in MRI studies, usually the EDSS (Kurtzke 
1983) and MSFC (Cutter 1999), have been widely criticized. Several studies, some 
in patients with PPMS (Kragt 2008), have demonstrated that the scales are 
unresponsive to disability accrual, and distinguish poorly between individuals 
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examining patients early in their disease course, within five years of symptom 
onset. Clinical rating scales tend to be most responsive in less disabled individuals 
(Kragt 2006), and epidemiological studies suggest that early progression rates may 
give an indication of future course (Cottrell 1999). A second problem is that 
although patients usually present with a paraparesis, relatively little attention has 
been devoted to spinal cord imaging. Thirdly, repair, remyelination, and functional 
reorganization may obscure the relationship between measures of brain injury and 
disability. Finally, the pathological processes driving disability accrual in PPMS 
may occur in areas which appear normal on conventional MRI: the normal 
appearing brain tissues (NABT). In recent years quantitative MRI techniques have 
been developed to address some of these problems. Although their application in 
the spinal cord was initially limited, technical improvements have led to a recent 
expansion in research into spinal cord injury in PPMS. Quantitative techniques are 
better able to reflect the balance of damage and repair in MS lesions, as confirmed 
by correlation with pathological studies. Most importantly, they have extended our 
understanding of the disease process in PPMS by allowing examination of the 
NABT.  
 
1.2.2 Non-conventional MRI measures 
 
Widespread abnormalities have been demonstrated in the grey and normal 
appearing white matter (NAWM) and in lesions in PPMS using non-conventional 
quantitative techniques, including spectroscopy, diffusion tensor imaging (DTI), and 
magnetization transfer imaging (MTI). Each of these modalities provides 
information about tissue damage, although their specificity for pathological 
processes is limited. In this section each technique is briefly described, and 
findings in the NABT, lesions and spinal cord in PPMS are summarized. Finally the 
findings in early PPMS are delineated. 
 
1.2.2.1 Spectroscopy 
Of the quantitative techniques, spectroscopy provides the most direct measure of 
tissue injury. Four major resonances are seen on proton MR spectra: N-
acetylaspartate (NAA), choline, lactate, and creatinine (Cr) (Filippi 2004). NAA is a                                                          Understanding progression in PPMS: Introduction     35 
putative marker of axonal integrity, and choline and lactate reflect demyelination 
and inflammation; however these relationships may be more complex, as 
demonstrated by studies in PPMS and other subtypes (Cader 2007, Sijens 2005). 
In PPMS, data from the PROMiSe trial analyzed by Narayana and colleagues 
showed NAA/Cr ratio reduction in both the NABT and in lesions (Narayana 2004). 
The indices did not correlate with disability or change over three years (Sajja 
2008). Another study, examining specific brain compartments in PPMS and SPMS, 
identified marked NAA reduction in the grey matter, with a less striking reduction in 
the NAWM (Sijens 2006). In early PPMS, NAA reduction has also been observed 
in both grey and NAWM; grey matter NAA changes correlated with disability 
(Sastre-Garriga 2005a).  
 
1.2.2.2 Diffusion Tensor Imaging (DTI) 
In DTI, the properties of water diffusion are used to examine tissue microstructure. 
The micro-architecture of a tissue limits and directs water motion, and tissue injury 
disrupts this architecture, allowing diffusion to occur freely in all directions. In DTI, 
a three dimensional tensor is constructed, and the magnitude of diffusion (mean 
diffusivity, MD) and degree of anisotropy (fractional anisotropy, FA) is measured 
(Filippi 2004). In a cohort including PPMS patients, Ciccarelli and colleagues 
identified widespread NAWM FA reduction, indicating tissue injury, and found that 
diffusion measures in the cerebral peduncles correlated with EDSS score. No 
difference in diffusion measures emerged between MS subtypes (Ciccarelli 2001). 
In another study, patients with progressive MS (including 54 PPMS patients) 
demonstrated tissue injury in the grey, NAWM and lesions, indicated by increased 
MD (Rovaris 2005). In 52 of these PPMS patients, followed up after 15 months, 
MD increased further in grey matter and lesions. Higher grey matter MD at 
baseline predicted clinical worsening at five years (Rovaris 2006). Reduction in FA 
and increase in MD has also been observed in the cervical cord in PPMS (Agosta 
2005). When MS subtypes were compared, PPMS patients demonstrated marked 
FA reduction in the cervical cord over two and a half years compared to RR and 
SPMS; in contrast, changes in cord MD and volume were comparable in the three 
groups (Agosta 2007).  
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1.2.2.3 Magnetization transfer imaging 
MTI is a particularly promising quantitative technique for the study of PPMS, 
because it is sensitive to the subtle pathological processes which cause tissue 
injury in the NABT. MT ratio (MTR) measures are derived from the MT images, and 
reflect the efficiency of magnetization exchange between macromolecules and 
tissue water (see section 2.8). MTR is altered by processes which affect the 
balance between macromolecules, most often related to myelin, and brain water. 
Animal and post mortem studies have shown that these processes include 
oedema, inflammation, and gliosis, but that MTR particularly reflects demyelination 
and axonal loss (Schmierer 2004, van Waesberghe 1999, Brochet 1999). In MS, 
MTR reduction has been shown to precede the appearance of lesions on T2-
weighted imaging (Filippi 1998), and  MTR provides an accurate quantitative 
measure of the extent of demyelination and repair within lesions (Chen 2007, 
Filippi 1999). In established PPMS, widespread clinically eloquent MTR reduction 
has been demonstrated in the NABT (Rovaris 2008) and also in the spinal cord 
(Nijeholt 2000). In early PPMS, MTR reduction is evident in the grey and NAWM, 
and correlates with disability (Ramio-Torrenta 2006) . 
 
1.3 Conclusions 
 
PPMS patients seldom experience relapses, and provide a relatively pure model 
for the study of progression in MS. This is reflected pathologically by comparatively 
modest focal inflammation and marked NABT injury. There are no effective disease 
modifying treatments for PPMS, and there are a number of challenges which 
impede clinical trials. MRI studies allow investigation of the disease process in 
vivo; however, correlation between conventional MRI parameters and clinical 
function are modest. Clinico-radiological correlation may be improved using 
quantitative techniques which assess disease burden more sensitively, through the 
inclusion of the NABT. Furthermore, targeting PPMS at the earliest stage, when 
disability accrual appears to influence future deterioration, may further augment 
clinico-radiological correlation. To date, studies in early PPMS have demonstrated 
marked, clinically eloquent injury to the NABT, as well as a surprisingly high 
proportion of active inflammatory lesions.                                                           Understanding progression in PPMS: Introduction     37 
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Magnetic resonance imaging (MRI) is a non-invasive technique used to image 
tissues in the human body in vivo. The first part of this chapter provides an 
overview of the basic principles of MRI; a full discussion of this complex subject 
necessitates an understanding of quantum mechanics, and is beyond the scope of 
this thesis. The latter part of the chapter discusses the sequences and post-
processing techniques employed in the studies described in this thesis. 
 
2.1 Nuclear magnetic resonance  
 
Atomic nuclei contain protons, which are positively charged particles, and 
neutrons, which have no charge. Nuclei with an odd number of protons exhibit 
nuclear magnetism, a form of paramagnetism. Materials with this property do not 
generate a net magnetic field, but are able to interact with an external magnetic 
field. This interaction is the basis of nuclear magnetic resonance (McRobbie 2003).  
 
The hydrogen atom has a nucleus consisting of a single proton. It is the most 
abundant atom in the human body and the most relevant paramagnetic nucleus for 
MR imaging studies. When it is placed in an external magnetic field (B0) it spins 
around its own axis, and thus exhibits a magnetic dipole moment or spin.  
At thermal equilibrium, the magnetic moment of each hydrogen nucleus is either 
aligned with B0, in a low energy state, or at 180˚ to B0 in a high energy state. There 
is a very slight excess of protons aligned in the low energy state, which gives the 
‘bulk’ or ‘net’ magnetization (M) in the direction of B0. The application of the 
external magnetic field causes the protons to rotate, or ‘precess’, around it, similar 
to the way a compass oscillates about the earth’s magnetic field (see Figure 2a). 
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Figure 2a: Precession of protons 
The external magnetic field, B0, is depicted as a large arrow 
behind the proton. The magnetic dipole moment of the proton 
aligns towards this, in the low energy state, giving a bulk 
magnetization vector of M, in the direction of B0. The proton 
precesses around B0, along the dashed line. In a substance with 
many protons, some protons will be in the low energy state, 
aligned towards B0, and some in the high energy state, aligned in 
the opposite direction.  M is the sum of all the individual dipole 
moments, divided by the volume of the substance. At equilibrium 
there is a small excess of protons in the low energy state, so M 
is aligned towards B0. 
 
 
The frequency at which the protons precess is called the Larmor frequency. It 
depends upon the strength of the external magnetic field, and a constant intrinsic 
to the nucleus, called the gyromagnetic ratio: 
 
Larmor frequency (ω0) = gyromagnetic ratio (γ) * external magnetic field (B0) 
 
ω0 is described in Herz (Hz) and B0 in Tesla. The stronger the magnetic field, the 
higher the Larmor frequency. For a hydrogen proton in a standard 1.5 Tesla 
scanner, the Larmor frequency is 64MHz. 
 
An external radio-frequency (RF) pulse is described as being on resonance if it 
oscillates at the Larmor frequency. It is able to transfer energy to, or excite, the 
hydrogen nuclei because it is oscillating at the same frequency at which they 
precess. This excitation increases the number of magnetic moments which are in a 
high energy state, and tilts the direction of net magnetization (M) away from B0. 
B0 
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2.1.1 The NMR signal 
 
The angle at which M is rotated away from B0, or the longitudinal axis, is called the 
flip angle, and it depends on the amplitude and the duration of the RF pulse. For 
example, a RF pulse applied orthogonally to B0 with a 90°  flip angle converts all 
the longitudinal magnetization into transverse magnetization, with M lying at 90°  to 
B0. The RF pulse also produces phase coherence, so that all the nuclei precess 
together in the transverse plane.  
 
The presence of a component of magnetization in the transverse plane induces a 
voltage in the MR scanner’s receiver coil, according to Faraday’s laws of induction. 
This is the NMR signal, and its magnitude depends on the magnetization vector; or 
the amount of magnetization in the transverse plane.  
 
2.2 Relaxation 
 
When the RF pulse is switched off, the protons lose energy and gradually return to 
thermal equilibrium, and the net magnetization returns towards B0. The signal 
observed during this relaxation process is called free induction decay (FID). 
Relaxation is achieved through two concomitant and independent processes: 
protons regain longitudinal magnetization (T1 relaxation) and lose transverse 
magnetization (T2 relaxation).  
 
2.2.1 T1 Relaxation (spin-lattice relaxation) 
 
When the RF pulse is turned off, nuclei lose energy to their surroundings, or lattice. 
Many of them return to a low energy state, so that M is once more aligned with B0, 
and longitudinal magnetization is regained. The time that this takes depends on the 
intrinsic properties of the tissue, and it is an exponential process. It is described by 
the time constant T1, or the time taken for 63% of the spins to regain longitudinal 
magnetization (see Figure 2b). This time constant is used to describe the 
exponential process. Understanding progression in PPMS: Chapter 2   51 
 
Figure 2b: The exponential curve for T1 relaxation 
At time T1, 63% of the longitudinal magnetization has been regained. 
 
 
 
 
 
 
 
 
 
   
2.2.2 T2 relaxation (spin-spin relaxation)  
 
After the RF pulse has been turned off, the protons gradually lose energy to their 
neighbouring nuclei, as their magnetic fields interact. This causes variations in the 
precession frequency of each individual nucleus, and so reduces phase coherence 
and thus transverse magnetization. This exponential process is governed by a time 
constant T2, which is the time at which only 37% of the transverse magnetization 
remains (see Figure 2c). 
 
Substances such as water are highly mobile with high inherent energy, while large 
molecules, such as fat, have a low inherent energy. Energy transfer is more 
efficient in larger molecules, and T1 relaxation time is therefore shorter in fat than 
water. There are greater spin-spin interactions when molecules are more tightly 
packed, thus protons in fats de-phase more rapidly and have a shorter T2 
relaxation time than those in water, where the spins are farther apart.  
However, the magnetic field inside a scanner is distorted by imperfections in the 
magnetic coil, and variations in the sample itself, so that it is not truly 
homogeneous. Therefore protons lose phase coherence faster than expected from 
T2 effects, at a rate described by the time constant T2*. T2* describes both the T2 Understanding progression in PPMS: Chapter 2   52 
relaxation intrinsic to a tissue, and the relaxation effects of the magnetic field 
inhomogeneities extrinsic to the tissue.  
 
Figure 2c: The exponential curve for T2 relaxation 
At time T2 the signal has fallen to 37%. 
 
        
 
2.3 The spin echo 
 
It is not possible to reverse the loss of phase coherence due to the intrinsic effect 
of neighbouring spins in a specific tissue (T2 effects). It is, however, possible to 
reverse the loss of phase coherence which is due to main field inhomogeneities. 
One method is the application of a second RF pulse, with a 180°  flip angle, to the 
de-phased nuclei. This has the effect of flipping the magnetic moments, so that 
those ‘further back’ along the precessional path are now ‘at the front’, and vice-
versa. Precession continues at the same speed, so the nuclei which were 
precessing faster, and now find themselves ‘further back’, are able to ‘catch up’ 
with those at the front. This puts the nuclei back in phase (after an interval 
matching the time between the first and the second RF pulse) so that the NMR 
signal increases again, and is described as a spin echo. The total time between the 
first RF pulse and the formation of the echo is called echo time, or TE. 
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2.4 Image Formation 
 
2.4.1 Spatial encoding 
 
In order to obtain an MR image from the signal in the receiver coil, it is necessary 
to be able to locate where the NMR signal is coming from. This is achieved using 
linear magnetic field gradients. There are two ways of obtaining MR images of a 
three dimensional (3D) object: two dimensional (2D) spatial encoding, and 3D 
spatial encoding. To create a 2 dimensional image, the sample is divided into 
slices (through slice-selection), each of which is then further differentiated by 
applying frequency encoding in one dimension, and phase encoding in another 
(see below). For 3D images, frequency encoding is applied in one dimension and 
phase encoding in the remaining two. 
 
2.4.1.1. Slice selection gradient (SS, Gslice, Gz) 
The slice-selection direction is often indicated with ‘z’, although it does not 
necessarily coincide with the direction of B0. A linear gradient is applied along the 
direction orthogonal to the planes to be imaged, so that the magnetic field changes 
strength at different locations along it. Thus at each location protons will precess at 
a different frequency to the rest of the sample. A RF pulse can therefore be applied 
at a frequency which is equal to the Larmor frequency of the protons at a specific 
location. In this way a specific slice of the sample can be selectively excited. 
 
2.4.1.2. Phase encoding gradient (PE, Gphase, Gy) 
The phase encoding gradient is applied along the direction conventionally indicated 
as ‘y’, prior to sampling, and alters the magnetic field strength at different points. 
This changes the precessional frequency of the protons at each point, so that 
nuclei along the gradient lose phase coherence. This makes the phase of the 
protons dependent on their position along the gradient. This allows protons to be 
located within a slice, and the greater the PE gradient the finer the detail of 
information obtained. This process is repeated a number of times N, which 
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2.4.1.3. Frequency encoding gradient (FE, Gread, Gx) 
A magnetic field gradient is applied in a direction orthogonal to the phase encoding 
gradient (the ‘x’ direction) during the measurement of the NMR signal. The 
frequency of the spins varies with the gradient, and so the signal changes with 
position along the gradient.  
 
Figure 2d demonstrates how these steps are employed in a spin echo sequence. 
At the echo time, TE, the signal is received. The next excitation pulse follows after 
the repetition time, TR, has elapsed.  
 
 
Figure 2d: The spin echo pulse sequence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A RF pulse is applied at 90˚, with a slice select gradient. This is followed by the frequency 
encoding and phase encoding gradients, and a rephasing pulse at TE/2. At time TE the 
signal is produced. Time TR is the time between one excitation and the next. 
R RF F 
G Gz z 
G Gx x 
G Gy y 
T TE E/ /2 2  T TE E/ /2 2 
9 90 0° °  1 18 80 0° ° 
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By varying the TR and TE, different contrasts in intensity can be achieved, to help 
differentiate between tissues. Shortening the TR helps differentiate tissues on the 
basis of their longitudinal relaxation (T1-weighting), because those with a long T1 
will not have had time to fully regain longitudinal magnetization before the next 
pulse. This reduces the transverse magnetization produced after the subsequent 
excitation, resulting in a smaller signal. Conversely, lengthening the TE helps to 
differentiate tissues on the basis of their T2-relaxation times (T2-weighting). It 
follows that a long TR and short TE minimises both T1 and T2 effects. In this case 
signal depends largely on the density of protons in the tissue (proton density [PD] 
weighting).  
 
2.4.2 k-space 
 
The receiver coil in the MR scanner receives information in the form of the NMR 
signal, and converts it into digits. Each digit represents the phase and frequency of 
signal at a specific point in time during scanning, and they are stored in an 
information matrix known as k-space. The order in which these data points are 
collected into k-space can be varied, but most often it is filled at regular intervals 
along the x and y directions. However, the trajectory always begins at the centre of 
k-space. The phase encoding gradient moves the trajectory vertically, along ky, and 
the larger the gradient the further away from the origin. Similarly, the frequency 
gradient moves the trajectory horizontally, along kx. Application of the 180˚ pulse 
will cause the trajectory to flip to the diametrically opposite position on the matrix. 
Low frequency, high amplitude data are recorded at the centre of k-space. They 
describe most aspects of the MR image, in particular the overall shape and 
contrast. High frequency, low amplitude data are recorded at the periphery of k-
space. They define areas of rapid spatial variation (such as edges), and therefore 
contain information about the finer details of the image. 
 
2.4.3 The Fourier Transformation 
 
To convert the information stored in k-space into an image, each data point 
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data from the time to the frequency domain. Each pixel in the image can then be 
allocated a colour on the grayscale corresponding to the amplitude of the 
frequencies, or signal intensity, recorded at that location.  
 
2.5 Sequences 
 
There are many ways in which the spin echo acquisition sequence can be altered, 
so that scanning time can be reduced and different types of contrast obtained. 
Below I will describe the acquisitions which have been used for the studies in this 
thesis. 
 
2.5.1 Fast/Turbo spin echo  
(also known as RARE (Hennig 1986), rapid acquisition with relaxation 
enhancement) 
 
In this sequence the 180˚ rephasing pulse is repeated, resulting in the formation of 
further spin echoes. The number of 180˚ pulses applied during TR is called the 
echo train length (ETL). After each new rephasing pulse, the phase encoding 
gradient is varied so that a different line of k-space can be filled for that slice. The 
scan time is decreased because the number of acquisitions necessary to fill k-
space is reduced by a factor equivalent to the ETL. However, the use of large 
ETL’s can result in image artefacts. Furthermore, it is necessary to control image 
contrast because each echo is acquired at a different TE, and therefore shows a 
different degree of T2-weighting. Image contrast is adjusted by assigning the 
echoes collected at the TE of interest to the low frequency signals, at the centre of 
k-space, where they have more influence on the image contrast. Those echoes 
collected at different TE’s are assigned to the edge of k-space.  
 
2.5.2 Interleaved or multi-echo sequences 
 
Images with different contrasts can be gathered at the same time by using different 
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dual-echo sequence the first image is obtained at short TE. The second image is 
then obtained after a further 180˚ pulse, so the TE is longer and the image is more 
T2-weighted. The phase encoding gradient is kept the same, so that the same line 
of k-space is filled in both images. In this way interleaved PD and T2 images of the 
same slice can be obtained at almost the same time, without increasing acquisition 
length. It is also possible to employ longer echo trains, where the first part of the 
echo train produces the PD image, and the second part the T2 image, but several 
lines of k-space are sampled in each TR. In the studies described in this thesis, we 
have used an interleaved sequence to acquire co-registered PD and T2-weighted 
images as part of the magnetization transfer sequence (see section 2.8.3). 
 
2.5.3 Gradient echo 
 
Gradient echo sequences differ from the spin echo because the excitation pulse is 
applied at a flip angle which is typically less than 90˚. This means that not all the 
longitudinal magnetization is converted to transverse magnetization, and TR and 
TE are reduced. In addition a gradient is used to rephase the protons instead of a 
180˚ pulse, which reduces the TE. Although the sequence is faster, it can not 
compensate for magnetic field inhomogeneities and is susceptible to artefacts.  
 
2.5.4 Three-Dimensional Fast Spoiled Gradient Recalled Echo (3D-FSPGR) 
 
In this 3-D T1-weighted acquisition, the third dimension is provided by an additional 
phase encoding gradient, applied in the same direction as the slice selection 
gradient. For each slab excited by the slice-select gradients, there is a given 
number of phase-encodings. Thus the slice thickness is the slab thickness divided 
by the number of phase encodings, and it can be reduced by increasing the 
number of partitions per slab, without limiting the RF amplitude. To produce T1-
weighting, the sequence can be preceded by an inversion RF pulse at 180° , which 
flips the longitudinal magnetization. Tissues begin their T1 relaxation from full 
saturation, so that the differences in their T1 relaxation times have greater 
influence on the signal produced. An RF excitation pulse is applied at a flip angle 
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to create an echo, as described above. However, because the TR is short, some 
transverse magnetization may remain when the next excitation occurs. This is 
destroyed using a spoiler gradient, which de-phases the spins. This acquisition has 
a high resolution and good differentiation between tissues. It is useful for 
examining brain structure and volume, and in our studies we have used it to 
measure brain atrophy (see section 2.7.1).  
 
2.6 Use of Contrast agents 
 
Altering acquisition parameters changes the contrast for the whole image. To 
specifically improve contrast in certain tissues, for example to differentiate between 
normal tissues and pathology, contrast agents are used to decrease T1 or T2 
relaxation times. 
 
2.6.1 Gadolinium 
 
Gadolinium is a trivalent lanthanide metal with seven unpaired electrons. Following 
intravenous injection, it extravasates from the cerebral circulation in areas where 
the blood-brain barrier is damaged by inflammation. It has a large magnetic 
moment which causes a fluctuation in the local magnetic field. This reduces T1 
relaxation time in the surrounding water molecules (McRobbie 2003), and 
produces a brighter signal on T1-weighted images (see Figure2e). 
 
 
  
Figure 2e: T1-weighted image after 
injection with triple dose gadolinium 
A gadolinium enhancing lesion is seen adjacent to 
the left frontal horn 
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In MS, gadolinium enhancement produces high signal in active inflammatory 
lesions, and most new lesions visible on T2 imaging enhance initially (Lee 1999). A 
number of studies have investigated how best to maximize the detection of new, 
active lesions. Imaging patients regularly (Tortorella 1999); including the spinal 
cord in the imaging protocol (Kidd 1993); imaging thirty minutes after injection 
rather than the standard five to seven minutes (Filippi 1995); using an MR 
sequence with thinner slices; using magnetization contrast for the images (Silver 
1997), and using high field MR (Sicotte 2003) all increase the number of enhancing 
lesions detected in MS. The most useful adaptation identified to increase sensitivity 
in RRMS, however, has been an increase in the gadolinium dose from single 
(0.1mm/kg) to triple (0.3mmol/kg) (Filippi 2000). In PPMS, relatively few studies 
have been performed and it has not been established whether triple dose 
gadolinium increases sensitivity. In one small study, triple dose gadolinium 
increased sensitivity to lesion enhancement (Filippi 1995), but in another it 
conferred no benefit (Silver 1997). 
 
To prevent toxic accumulation in body tissues, gadolinium is chelated with DTPA 
(forming gadolinium-diethylenetriaminepenta-acetic acid), so that it can be safely 
excreted by the kidneys. However, recent case reports of nephrogenic systemic 
fibrosis developing in patients with renal impairment have resulted in Food and 
drug administration (FDA) recommendations that renal function is always tested 
before gadolinium administration. There is a small risk of anaphylaxis, and the drug 
should only be given under medical supervision with resuscitation equipment and 
drugs to hand. Patients should be fully informed of the reasons for contrast 
administration, and the potential risks, prior to imaging.  
 
2.7 Measuring brain volume 
 
There are a wide variety of rapidly evolving techniques available to measure brain 
volume and atrophy from MRI. This section briefly discusses some of the 
techniques most commonly employed in multiple sclerosis imaging studies. 
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Specific areas of interest, or indeed the whole brain, may be outlined manually in 
two dimensions, and measured. In MS, the corpus callosum has often been 
studied in this way (Paolillo 2000), as a site of particular disease predilection. The 
technique is straightforward but time consuming, and limited by problems of intra- 
and inter-observer reproducibility. The use of simple individual measurements of 
ventricular dimension, which can be used as markers for atrophy, has also been 
explored (Butzkueven 2008).  
 
2.7.1 Segmentation-based techniques 
 
This type of analysis involves separating segments of the brain from surrounding 
structures, and then measuring the volume of tissue within them. Segmentation on 
serial MRI allows measurement of the rate of atrophy. A semi-automated technique 
to measure central cerebral volume (Losseff 1996) has been  widely used in PPMS 
(Stevenson 1999). This technique concentrates on between four and six axial 
slices (depending on slice thickness) at the centre of the brain, a common site for 
peri-ventricular lesions which is particularly vulnerable to atrophy. The brain is 
segmented from the relevant image slices using an optimum intensity threshold 
that removes non-brain structures. Manual editing may be necessary, which limits 
reproducibility, and the accuracy of the technique is very dependent on slice 
thickness and patient positioning within the scanner. SIENAX (Structural Image 
Evaluation, using Normalization, of Atrophy cross-sectional) is an alternative 
segmentation-based package (Smith 2002), in which the brain is extracted from the 
image using a tessellated mesh to model the surface, followed by application of a 
brain mask in stereotactic space to remove extra-cerebral tissue. Further grey 
matter, white matter and CSF segmentation is carried out on this extracted brain 
image in order to determine brain volume. This technique also includes an 
estimation of partial volume effects, and therefore greater volumetric accuracy, as 
well as automatically normalizing the brain volume for head-size thereby making 
cross-sectional analyses more sensitive. Manual editing may improve accuracy, 
and does not compromise the high inter-centre reproducibility (Jasperse 2007). 
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identifies the brain/CSF boundary in order to segment the whole brain, or CSF in 
order to calculate ventricular volume (Dalton 2006). 
 
In the work described in this thesis, the SPM99 and SPM2 packages (Statistical 
Parametric Mapping; Wellcome Department of Cognitive Neurology, London, 
UK)(Ashburner 1997) have been applied to segment 3-D FSPGR images (see 
section 2.5.4). All images are normalized to a template, based on the Montreal 
Neurological Institute template, and extra-cranial tissues are removed. Intensity 
inhomogeneities are corrected. Segmentation proceeds according to an a priori 
template derived from a database of normal brain images, in addition to information 
from individual pixel intensities. A probability map is produced, wherein each voxel 
is assigned a probability of belonging to a specific tissue class (see Figure 2f). The 
use of normal brain templates may pose problems when pathology markedly alters 
subjects’ brain morphology, for example in brains with severe atrophy or a very 
high lesion load. Another problem for MS studies is that white matter lesions may 
be erroneously classified as grey matter (Anderson 2006). This problem is 
addressed by applying a lesion mask following segmentation, which overrides local 
tissue classifications in order to remove lesions from the volume measurement.  
 
A recent study compared three brain volumetry methods for measuring grey and 
white matter: FAST, the segmentation tool from the FSL library 
(http://www.fmrib.ox.ac.uk/fsl); Freesurfer, an automated surface reconstruction 
tool for measuring cortical thickness (Fischl 2002), which also contains an 
automated segmentation algorithm; and SPM5, an updated version of SPM2.  
SPM5 was most consistent in measuring segment volumes longitudinally; however, 
maximum deviations of 3% occurred even with this technique, indicating the 
current limitations of sequential atrophy measurements (Klauschen 2008).  
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Figure 2f: Segmentation of FSPGR image in SPM2 
 
                                               
                                                  Original   FSPGR 
                              
                     Grey matter              White matter                      CSF 
 
The 3-D FSPGR image is segmented into grey matter, white matter and CSF using SPM2. 
Note the inclusion of peri-ventricular lesions, around the posterior horn of the lateral 
ventricle, in the grey matter segment; these are later removed by lesion masking. 
 
2.7.2 Registration-based techniques 
 
These methods provide a direct measure of brain volume change between serial 
images by matching the position of, or registering, the images. This may address 
the limitations for sequential segmentation-based measures described above. For 
example, SIENA (Structural Image Evaluation, using Normalization, of Atrophy) 
uses a tessellated mesh to model the edge of the brain surface, and shifts in this 
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a technique which measures atrophy based on the difference in brain voxel 
intensities between registered images at the brain/CSF boundaries (Fox 1997). 
However, although these techniques may be more precise than segmentation-
based approaches in assessing whole brain volume change over time (Anderson 
2007), they can not examine specific brain segments, and lesions can not be 
removed from the analysis. 
 
2.7.3 Voxel-based morphometry (VBM) 
 
This fully automated technique localizes atrophy without an a priori hypothesis, 
providing an unbiased survey of the whole brain, or more usually the grey matter. 
Information about localized atrophy is lost using the whole-brain techniques 
described above, because areas of atrophy may be counterbalanced by relatively 
normal areas. In VBM, all images are registered to a template, so that the tissue 
concentration (or density) at each voxel can be compared between subject groups 
(Ashburner 2000). Areas where the tissue concentration in one group significantly 
differs from that in the other group are highlighted. Thus only regions where a 
significant proportion of the subjects have atrophy are identified, and there is less 
sensitivity to changes between groups in areas of high natural variance (Anderson 
2006). In addition this method does not provide absolute measures of volume or 
atrophy for individual subjects. 
 
There have been concerns that changes identified on VBM may be due to mis-
registration, patient positioning or other artefacts rather than to actual differences in 
brain volume (Bookstein 2001), and that localizing changes on normalized, 
smoothed images may be misleading (Smith 2006). In addition, methodological 
variations such as the size of the smoothing kernel may have considerable impact 
on results (Jones 2005). Particular challenges in multiple sclerosis studies include 
the normalization of images after lesions have been removed (Audoin 2004).  In 
the VBM study described in Chapter 4, we have attempted to address uncertainties 
regarding the accuracy of localization by performing a post-hoc analysis of our 
results. As we have confined our analysis to the grey matter, removal of visible T2 
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weighted lesion mask meant that voxels classified as containing lesions were not 
considered during the normalization. However, the strengths and limitations of this 
novel technique must be borne in mind when interpreting the results (see section 
4.4.1.4). In this study we also applied a voxel-based approach to the analysis of 
MTR images, as discussed in the next section.  
 
2.8 Magnetization Transfer Imaging (MTI) 
 
Much of the work described in this thesis is based on the use of magnetization 
transfer imaging (MTI), a semi-quantitative MRI technique based on cross-
relaxation and chemical exchange between protons in free water and those bound 
to macromolecules. Bound protons are often associated with proteins, such as 
myelin, and are restricted in their movement by the chemical environment. The 
proximity of other protons increases spin-spin interactions and reduces their T2 
relaxation time, so that they are far less visible than free water protons on most MR 
sequences. However, using MTI the properties of the bound proton pool can be 
indirectly explored.  
 
2.8.1 MTR 
 
Protons in the bound pool are constantly exchanging magnetization with the free 
proton pool. They tend to have a very broad spectrum of precessional frequencies 
due to their varying molecular structures and to the local interaction with 
neighbouring spins. In contrast, free water protons all precess at similar 
frequencies. This makes bound protons sensitive to off-resonance radiation, at 
frequencies other than the Larmor frequency, and allows a preparatory off-
resonance RF pulse to saturate (reduce to zero) the magnetization of bound 
protons with minimal direct effect on free protons. However, the bound protons 
then transfer magnetization to the free pool, via cross relaxation and chemical 
exchange. This reduces the PD-weighted signal (Ms) obtained in areas where there 
are bound protons, because the transverse magnetization of the free water protons 
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saturation pulse (M0), and the difference between the two signals in each voxel 
gives the MTR: 
 
MTR= 100 (M0- Ms/ M0) per cent units (pu) 
 
The MTR of a voxel is thus an indication of the size of the bound proton pool in that 
voxel, and is higher when the bound proton pool is larger. In the brain CSF, like 
free water, has an MTR value close to zero. White matter is abundant in myelin, so 
the bound proton pool is large and the MTR high. In the grey matter, there are 
fewer bound protons than white matter, but more than in CSF, and the MTR is 
intermediate.  
 
2.8.2 Factors influencing MTR in vivo  
 
There are several considerations which reduce the accuracy and applicability of 
this model in clinical practice. These relate to either the tissues themselves or the 
MR scanner. 
 
2.8.2.1 Properties of the tissue 
Essentially, MTR is determined by the exchange rate between the free and bound 
proton pools, and the size of the bound proton pool, but it is also influenced by the 
T1 relaxation time of the free water. Magnetization destruction is determined by the 
magnetization exchange rate multiplied by the size of the bound pool, and 
magnetization recovery by the inverse of the free water T1 relaxation time. This 
means that where there is pathology MTR may lose some sensitivity. For example, 
in an MS lesion, there is a reduction in myelin and therefore a reduction in the 
bound proton pool. However, there is a concomitant increase in T1 relaxation 
which counteracts this effect, resulting in only a very small change in the overall 
MTR. Thus the MTR reduction does not reflect the full extent of demyelination 
(Tofts 2004). However, the T1 effect is relatively small, and is minimized in our 
studies using a PD rather than T1-weighted acquisition sequence (McGowan 
1999). Another consideration is that some direct saturation of the free pool is 
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safely in vivo. However, it has been shown that greater saturation of the bound 
pool is not necessarily optimal for studying pathology in MS (Graham 1999) .  
 
2.8.2.2 MR scanner parameters 
The MTR is also affected by the offset frequency selected, the bandwidth, 
amplitude and duration of the MT pulse (Tofts 2006). Typically, the MT pulse is 
Gaussian or sinc, with a bandwidth of a few 100Hz, delivered at 1-5kHz off the 
frequency of the mobile water. Care must also be taken to accurately set the flip 
angle and to minimise transmit field non-uniformity, for example by using body coil 
excitation, to achieve a reproducible MTR (Tofts 2006). 
 
In the work presented in this thesis, the considerations above are addressed 
because MTR is always compared between patients and normal controls, and all 
scans are performed on the same scanner, using the same parameters at each 
acquisition.  
 
2.8.3 MT sequence 
 
The MT sequence described in this thesis is an interleaved acquisition, producing 
inherently co-registered saturated and unsaturated PD-weighted MT images, a PD 
image, and a T2 image, for each slice (Barker 1996). Using an interleaved spin 
echo acquisition is relatively slow. To speed the acquisition, the saturated images 
for multiple slices are collected during one sequence, and then the unsaturated 
images. The TR is also reduced to speed up the acquisition, and this may increase 
T1-weighting. However, the production of co-registered images of different 
modalities is extremely helpful for lesion identification and marking, and the 
creation of accurate lesion masks.  
 
2.8.4 Post-processing 
 
Once the MTR for each voxel has been calculated according to the formula 
described above, an MTR map is created (see Fig 2g), which can be processed 
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Figure 2g: MTR image  
The image is derived from the saturated  
and unsaturated PD-weighted MT images 
 
 
 
 
 
 
 
2.8.4.1 Region of Interest (ROI) Analysis 
This process necessitates the a priori selection of a region for study, which is 
contoured on a suitable co-registered image and applied as a mask to the MTR 
map, to extract the MTR in specific voxels.  The ROI contouring may be manual or 
partly automated, depending on the structure to be examined, and this introduces a 
margin for error. Alternatively, the ROI may be represented by a box placed at 
specific co-ordinates in the brain; in this case, accurate ROI placement may be 
particularly problematic in serial studies. Only a limited number of areas may be 
examined in this way; too many comparisons necessitate Bonferroni corrections 
and thus lose sensitivity (Tofts 2004). In MS,  an ROI approach was initially 
employed to examine the normal appearing brain tissues (Leary 2000); however, 
this application has been superseded by more robust techniques, allowing 
unbiased examination of the whole NABT.  
 
2.8.4.2 MTR Histogram Analysis 
This technique is fully automated, relatively fast, and highly reproducible (van 
Buchem 1999). It involves the creation of a frequency distribution from the values 
in the MTR map, and allows modelling of the whole brain without an a priori 
hypothesis. If required, lesions can be masked and removed, and tissues can be 
segmented using automated algorithms, to obtain the MTR of the whole grey or 
NAWM.  Understanding progression in PPMS: Chapter 2   68 
 
The MTR histogram obtained from a normal brain demonstrates a single peak with 
a fairly narrow range of values (van Buchem 1997). Several considerations are 
involved in creating histograms. The values included in the histogram are often 
integers, because images tend to be stored as integers to limit the amount of 
memory required, and so continuous intensity values have been rounded up or 
down. This produces spikes in the histogram, which can be smoothed by the 
addition of random noise to the intensity value before conversion into MTR, called 
a pseudo-continuous distribution (Tozer 2003). The intervals into which MTR 
values are divided in a histogram is called the bin width, and in the studies 
described in this thesis we have chosen a bin width of 0.1 pu (see Chapter 3 
section 3.1.2.3). This is a trade-off between wider bin sizes, which can smooth 
away accurate localization and measurement of the peak, and the excess noise 
produced by very narrow bins (Tofts 2004). Initially, the area under the histogram 
curve gives the total number of voxels, so that the tissue volume is calculated by 
multiplying by the volume of one voxel. However, due to the wide variation in brain 
sizes, histograms are normalized to make them comparable. Each histogram value 
is divided by the sum of all the values and by the bin width, so that the area below 
the histogram becomes unity. The normalized histogram therefore shows the 
fraction of total brain volume lying at each MTR interval. 
 
Specific parameters which describe the histogram can be extracted (see Figure 2h) 
and in our studies we have used peak height (PH), peak location (PL) and mean 
values. Histogram PH appears to be the most sensitive to decline in MS (van 
Buchem 1996, Zhou 2004), indicating a reduction in voxels at the most popular 
MTR value of the normal range. For this reason it has been claimed that histogram 
PH represents the amount of ‘normal’ brain parenchyma remaining in the segment 
(van Buchem 1996). However, PH also tends to be the most variable parameter as 
it is vulnerable to artefact; for this reason it may not be the best parameter to 
distinguish between patients and controls (Zhou 2004). The mean MTR is closely 
related to the PH, but it is less sensitive to change as more voxels at lower MTR 
are needed to shift the mean value of the whole histogram. The peak location (PL), 
which is the mode of the values, is closely related to the mean, and moves to the Understanding progression in PPMS: Chapter 2   69 
left after considerable increase in voxels with a lower MTR. Some studies have 
included features which further describe the shape of the histogram, giving more 
information about pixels at lower values, such as the 25
th and 75
th centiles (Ramio-
Torrenta 2006). Zhou et al proposed using the area under the histogram at a width 
of 2/3 the histogram height, to encompass a wider variety of information about the 
histogram peak and distribution (Zhou 2004), and McGowan et al proposed using 
the mean +/- standard deviation (SD) (McGowan 2000). Attempts have also been 
made to use more complex analyses which represent the features of the histogram 
more completely, such as principle component analysis (Dehmeshki 2001) and 
more recently analysis of skew (Hayton 2009).  
 
Histograms are very sensitive to subtle diffuse change, because an average is 
taken from a large number of voxels, thus reducing the effect of noise. For this 
reason they are not ideal for analyzing small tissue volumes, such as lesions. They 
can be created from larger ROIs, but are extremely sensitive to slight changes in 
ROI positioning. In addition, the sensitivity of histogram analysis for the detection of 
very localized pathology is limited, because changes may be compensated for by 
normal areas. Generalized information about the segment under study is provided; 
all information about location is lost (Tofts 2004).  
 
Figure 2h: Histogram of the grey matter MTR in a patient with PPMS 
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2.8.4.3 Voxel-based MTR Analysis 
MTR changes can be localized using a voxel-based approach, as described in 
section 2.7.4. A mask of the area under study, for example the grey matter, may be 
created and applied to the MTR image (see Chapter 4), or the MTR image itself 
may be segmented (Audoin 2006). The MTR in each voxel can then be compared 
between groups. It is important to consider partial volume voxels, particularly in 
areas of localized atrophy. These occur when a voxel contains tissue from outside 
the segment under study; for example, some NAWM or CSF may contaminate a 
grey matter voxel and alter its MTR. In the study described in Chapter 4, we have 
addressed this issue by applying a 75% likelihood threshold to the grey matter 
mask, so that all voxels included are more than 75% likely to contain grey matter 
(see section 4.4.1.4). Other investigators have employed an erosion step, where 
the outer grey matter voxels are removed (Mesaros 2008); we avoided this 
because it indiscriminately reduces the number of grey matter voxels studied.  
 
2.9 Conclusions 
MRI exploits the paramagnetic properties of tissues by applying a radiofrequency 
pulse in the presence of an external magnetic field. Images are encoded using 
linear magnetic field gradients and recorded in k-space. Variations in acquisition 
can be used to manipulate image contrast. Contrast within an image can be altered 
using contrast agents such as gadolinium. The brain volume measurements 
performed in later chapters are calculated from 3-D FSPGR images using SPM2. 
The MT sequence used is an interleaved acquisition producing inherently co-
registered PD- and T2-weighted images. 
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This chapter contains two longitudinal studies which investigate progression in 
PPMS using MTR histograms. The first explores the sensitivity of MTR 
histograms for detecting short term changes in the brain over one year, and the 
potential for baseline MTR histograms to predict short term progression. The 
second study investigates whether the predictive value of MTR histograms is 
maintained over a longer period of three years, and whether MTR histogram 
parameters change concurrently with clinical measures during the study. In both 
sections, brain atrophy is also considered, both for its capacity to affect MTR 
measurements and its potential relevance to disease progression.  
 
3.1 Detecting change and predicting progression over one year 
in early PPMS 
 
3.1.1 Introduction 
Magnetization transfer imaging quantifies injury in the NABT and in lesions by 
measuring the MTR. A reduction in MTR is thought to reflect demyelination and 
axonal loss (Schmierer 2004), thus the technique is particularly suited for 
exploring the disease processes driving clinical progression in PPMS. The basis 
of the MTR measurement is fully discussed in section 2.8. Diffuse 
abnormalities, reflected by reduction in MTR, have been identified in the NABT 
of subjects with PPMS (Dehmeshki 2003, Gass 1994). Some studies suggest 
that the changes are less profound than those seen in SPMS (Vrenken 2007, 
Rovaris 2000), but others have described an equivalent amount of damage 
(Dehmeshki 2001). Initially, correlations between MTR and clinical indices in 
established PPMS appeared weaker than in other MS subtypes (Dehmeshki 
2001, Filippi 2000a), and short-term longitudinal studies did not demonstrate 
MTR changes despite concurrent increase in T2 lesion load (Filippi 2000b). 
However, a cross-sectional study in early PPMS demonstrated a correlation 
between MTR reduction (in both grey and NAWM) and clinical function (Ramio-
Torrenta 2006), suggesting that MTI may be sensitive to longitudinal changes in 
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Brain atrophy represents irreversible tissue damage, and is thought to be a 
reflection of axonal loss (Simon 2006). Brain atrophy is already evident in 
patients with early PPMS, in both the grey and NAWM segments (Sastre-
Garriga 2004), and the extent of volume loss correlates with clinical function. 
Any investigation of MTI in PPMS must also consider brain atrophy, for two 
reasons. Firstly, volume loss interferes with MTR measurement by increasing 
‘partial volume’ voxels: voxels which only partly contain either grey or NAWM. 
Voxels containing both tissue types would generate an MTR intermediate to that 
of a purely grey or NAWM voxel, and those containing NABT and CSF together 
would have a markedly reduced MTR. For this reason, care must be taken in 
post-processing to minimize partial volume voxels, and statistical correction for 
atrophy may also be necessary to ensure that any remaining contribution of 
volume loss to the MTR measurement is taken into account. Secondly, MTR 
reduction is thought to reflect both reversible processes (principally 
demyelination, but also gliosis and inflammation) and irreversible processes 
(particularly axonal loss), although there is some indication that the former may 
be more directly related to MTR (Schmierer 2004). Thus models taking full 
account of concurrent volume change when measuring MTR may be more likely 
to highlight the contribution made by reversible processes, potentially gaining 
complementary information to that obtained from volume measurements. 
The only previous longitudinal MTR study in PPMS examined nine patients with 
PPMS as part of a mixed MS cohort, using NABT MTR histograms over one 
year. No change in MTR parameters was observed, despite an increase in T2 
lesion load over the same period (Filippi 2000b). In this study we explored the 
value of baseline MTR to predict clinical progression in the short-term, and 
investigated whether MTI was sensitive enough to detect changes over one 
year in early PPMS, independently of any contribution from brain atrophy.  
3.1.2 Methods 
3.1.2.1 Subjects 
 
The participants in this study were recruited as part of a cohort of fifty patients 
with definite or probable PPMS (Thompson 2000), within five years of symptom 
onset, who were participants in a longitudinal study comprising six monthly Understanding progression in PPMS: Chapter 3     77   
radiological and clinical assessments. For this study we examined data 
obtained at baseline and after one year. One patient did not complete the 
baseline protocol, and two patients were excluded after baseline: one 
developed claustrophobia and one withdrew. Eleven patients did not attend at 
one year, the reasons were as follows: death, not MS related (1), illness 
unrelated to MS (2), personal commitments (6; in these cases patients were 
away from London or prevented from attending their appointment due to prior 
commitments). Two patients missed their one year time-point due to the 
scanner upgrade. In addition, three patients were scanned after the scanner 
upgrade, and excluded from this study, and two patients had not yet reached 
their one year time-point. Finally, one patient was excluded because all images 
were of sub-optimal quality (see section 3.1.2.3). Thus the subgroup for this 
study was composed of 30 patients (17 male, 13 female, mean age 42.1 years 
[range 25-63]). Patient characteristics are given in Table 3.A. None of the 
patients were taking disease modifying medications, but one patient was taking 
regular courses of oral steroids every three months. Patients were recruited 
from clinics at the National Hospital for Neurology and Neurosurgery and other 
hospitals in Southeast England. Written and informed consent was obtained 
from all participants. The study was approved by the Joint Medical Ethics 
Committee of the National Hospital for Neurology and Neurosurgery and the 
Institute of Neurology, London. 
Patients underwent neurological examination at baseline and one year. They 
were scored on Kurtzke’s Expanded Disability Status Scale (EDSS) (Kurtzke 
1983) . The Multiple Sclerosis Functional Composite (MSFC) (Cutter 1999) and 
its subtests (Paced Auditory Serial Addition Test [PASAT], Nine Hole Peg Test 
[NHPT], and Timed Walk Test [TWT]) were performed for the first time at 
baseline (without previous practice sessions) and on 22 of the patients at one 
year (12 male, 10 female, mean age 41.9 years [range 25-63]). There was no 
significant difference in baseline EDSS, MSFC, T2 lesion load or brain 
parenchymal fraction (BPF), or in one year EDSS, T2 lesion load, or BPF 
between those patients scored for MSFC at one year and those who were not.  
Fifteen healthy controls (9 male, 6 female, mean age 35.4 years [range 27-52]), 
were also scanned at baseline and one year. The difference in age between 
patients and controls was adjusted for in the statistical analysis. Understanding progression in PPMS: Chapter 3     78   
Table 3.A Clinical characteristics of patients at baseline and follow-up 
Characteristics  Baseline  One year  P value 
Number male / female  17/13  -  - 
Mean age in years (range)   42.06 (25-63)    -    - 
Mean disease duration in years (range)  2.9 (1-5)  -  - 
Presentation: cord/non-cord symptoms  23 / 7  -  - 
Median EDSS (range)   4.0 (1.5-7)    4.75 (2-7.5)    p=0.02 
Mean MSFC (SD)  0.05 (0.84)   0.02 (1.07)  p=0.8 
Mean PASAT (range)  43.0 (0-60)    46.0 (3-60)  p=0.3 
Mean NHPT (range)  34.3 (17.1-96.2)    40.9 (18.0-165.8)  p=0.2 
Mean TWT (range )  17.6 (3.65-180)   23.9 (3.70-180)  p=0.4 
 
P values were obtained from Willcoxon rank tests (EDSS) and paired t-tests (all other 
variables) to compare baseline and follow-up values. EDSS=Expanded disability status 
scale, MSFC= Multiple sclerosis functional composite, PASAT= Paced auditory serial 
addition test, NHPT=Nine hole peg test, TWT=Timed walk test, BL=Baseline, 
FU=follow-up, SD=Standard deviation. 
 
3.1.2.2 MRI Acquisition 
 
All scans were performed at baseline and after one year on a 1.5 Tesla GE 
Signa scanner (General Electric Co, Milwaukee, Wisconsin, USA). The mean 
and median separation of baseline and one year scans were both 12.3 months 
(range 10.1 - 15.2 months).  
 
MTI was acquired using a 2D interleaved spin echo sequence described by 
Barker et al (Barker 1996), comprising 28 contiguous axial slices, slice 
thickness 5mm, repetition time (TR) 1720ms (milliseconds), echo time (TE) 
30/80 ms, number of excitations (NEX) 0.75, acquired matrix 256x128, 
reconstructed matrix 256x256 and field of view (FOV) 240x240mm. Proton 
density (PD)-weighted images were acquired in the presence and absence of a 
Hamming-apodised three lobe sinc MT pulse (duration 16ms, peak amplitude 
23.2 µT[micro-Tesla], bandwidth 250 Hz [Herz], 1kHz [kilo-Herz] off-water 
resonance). These saturated and unsaturated PD MT sequences were co-
registered and interleaved with simultaneously acquired PD and T2-weighted 
images.  Understanding progression in PPMS: Chapter 3     79   
All subjects also underwent a 3D inversion-prepared fast spoiled gradient recall 
(3D FSPGR) sequence of the brain, comprising 124 contiguous axial slices, 
slice thickness 1.5mm, TR 13.3 ms, TE 4.2ms, inversion time 450 ms, matrix 
256x160 [reconstructed matrix 256×256, final in plane resolution 1.17x1.17 mm] 
and FOV 300 x 225mm.  
3.1.2.3 Image Post Processing 
 
Images were displayed on a Sun workstation (Sun Microsystems, Mountain 
View, CA, USA) using DispImage software (DispImage, D. Plummer, 
Department of Medical Physics and Bioengineering, UCL, UK). Lesions were 
delineated with a semi-automated contour thresholding technique (Plummer 
1992) on the unsaturated PD images, with reference to the co-registered T2 
images, and used to create a binary lesion mask (setting the signal inside the 
lesion boundary to 0, and the rest to 1). 
3.1.2.3.1 MTI 
The pixel MTR was calculated from the pre- (Mo) and post- (Ms) saturation PD-
weighted images using the formula [(Mo-Ms)/Mo] x 100 percent units (pu), to 
produce MTR maps for each subject. These images were chosen because the 
resulting map has higher signal-to-noise ratio than that from the 80ms echo. 
The T2 images were segmented in SPM99 (Statistical Parametric Mapping 
1999, Wellcome Department of Cognitive Neurology, London, England) using 
an algorithm based
 on cluster analysis combined with a priori knowledge of 
tissue
 distribution (see section 2.7.1) (Ashburner 2000), which assigns voxels to 
white matter, gray matter or CSF. We used SPM99 so that our results would be 
comparable to those from a previous cross-sectional study in our cohort 
(Ramio-Torrenta 2006). Non-brain tissue, whole brain (WB), white matter and 
grey matter probability maps were produced, and used to create WB, grey and 
white matter masks, which were then applied to the calculated MTR map in 
each subject to produce WB, grey and white matter MTR maps. To minimise 
partial volume voxels, we employed a 10pu threshold, and eroded the outer and 
inner layer of voxels twice in the white matter, and once in the grey (the cortical 
grey matter was too thin to support further erosions). The segmentation of the 
MTR images was checked manually in all subjects. One patient’s scans were 
incorrectly segmented, with white matter accidentally included in the grey matter Understanding progression in PPMS: Chapter 3     80   
segment due to a very high lesion load. This patient was excluded from the 
analysis.  
 
The T2 lesion masks were then applied to the WB, grey and white matter MTR 
maps to produce grey and NAWM probability maps. We have avoided the term 
normal appearing grey matter because while all visible T2 lesions were 
removed, grey matter lesions are not visible on T2-weighted images at 1.5 
Tesla (Geurts 2005b). To obtain the lesion MTR map, the lesion mask was 
reversed (setting the signal inside the lesion boundary to 1, and the rest to 0), 
applied to the grey and white matter probability maps to produce a lesion 
probability map, and then to the MTR images to produce a lesion MTR map. In 
the case of controls, where no lesions were found, segmentation produced 
normal white matter (NWM) and grey matter maps. MTR histograms were 
obtained for the grey, NAWM and lesions in patients, and grey matter and NWM 
in controls. To allow us to compare MTR histograms between subjects, the 
MTR histograms of each segment were normalized to the volume of that 
segment. The histograms had a bin width of 0.1 pu and a smoothing window of 
0.3 pu. Mean, peak height (PH) and peak location (PL) MTR measures were 
taken from each individual histogram. 
 
3.1.2.3.2 Atrophy 
At each time-point lesions were contoured on the individual FSPGR scans using 
the software described above, to create a T1-weighted lesion mask. The 
observer was blinded to the clinical details. FSPGR images were segmented 
into white matter, grey matter and CSF using SPM99, and the volume of each 
segment calculated as described by Chard et al (Chard 2002b). The lesion 
mask was then subtracted from the white matter and grey matter T1 images 
and separate NAWM, grey matter and lesion segments were obtained, with 
their volumes in ml. Volume estimations were made using a caudal cut-off at the 
last slice containing cerebellum. The total intracranial volume (TIV), BPF, 
normal appearing white matter fraction (NAWMF) and grey matter fraction 
(GMF) were calculated as follows: 
 
TIV = lesion volume (LV) + NAWM volume (NAWMV) + GM volume (GMV) + 
CSF volume Understanding progression in PPMS: Chapter 3     81   
BPF = (LV+ NAWMV+ GMV) / TIV 
NAWMF = NAWMV / TIV  
GMF = GMV / TIV 
3.1.2.4 Statistical Analysis  
 
Analysis was carried out using SPSS 10.0 (Statistical package for the Social 
Sciences, Chicago, IL, USA). Statistical significance is reported at the 5% level. 
Significant values for correlation coefficients are reported without correction for 
multiple comparisons to avoid type II errors (Perneger 1998). 
 
3.1.2.4.1 Clinical data 
In analyzing the change in EDSS scores, a one step deterioration on the scale 
was defined as an increase of one if the baseline EDSS was less than or equal 
to five or an increase of 0.5 if it was greater than five (Ellison 1994). This gives 
greater weight to change in more disabled patients, in whom deterioration is 
harder to detect on the EDSS scale, and these steps have been regarded as 
equivalent in clinical trials (Hoogervorst 2003). Z-scores (z) were derived for the 
MSFC subtests using our own baseline sample as reference, and used to 
calculate the MSFC. One patient at baseline and two at one year were too 
disabled to complete the TWT, and were scored with the maximum time allowed 
for the TWT (180 seconds), as described by Hoogervorst et al (Hoogervorst 
2002).  
 
3.1.2.4.2 Baseline MTR predictors 
To find whether baseline MTR in patients predicted clinical change, multiple 
linear regression analyses were performed for each clinical test and subtest, 
and each MTR parameter in each segment. Clinical score at one year was the 
dependent variable, and clinical score at baseline and baseline MTR 
parameters were independent variables, so that any relationship identified 
between baseline MTR variables and change in clinical score would be 
independent of any relationship between baseline MTR variables and baseline 
clinical score. Models were adjusted for age, gender and baseline intra-
segmental volume ie WB analysis was adjusted for baseline BPF, NAWM for Understanding progression in PPMS: Chapter 3     82   
NAWMF and grey matter for GMF. Where significant correlations were found 
between baseline MTR parameters and clinical change, the strength of the 
association was assessed using partial correlations adjusted for age, gender 
and intra-segmental volume. 
To investigate further the utility of baseline MTR measures in predicting clinical 
change, patients were divided into two groups: those with a stable EDSS score 
at one year, and those who had worsened. The MTR parameter that most 
strongly predicted EDSS changes was chosen. A cut-off value for this MTR 
parameter, which was below the lowest value in controls, was chosen. Patients 
were divided into a further two subgroups depending on whether their MTR was 
below or above this value. A two by two table was constructed, showing the 
number of patients with low and normal MTR against those who were stable or 
worsened on EDSS. The sensitivity, specificity, positive and negative predictive 
values, and overall accuracy of using this MTR parameter to predict clinical 
worsening were calculated according to standard methods (Greenhalgh 1997). 
3.1.2.4.3 MTR change over one year in patients and controls 
To determine MTR change over one year, paired t-tests were used to compare 
MTR at baseline and one year within patient and control groups. Multiple linear 
regression analysis was then used to compare changes in each segmental 
MTR parameter between patient and control groups, adjusting for age and 
gender.  
 
3.1.2.4.4 Relationship between MTR and atrophy 
Pearson’s correlations were performed to establish the relationship between 
change in MTR and brain volume in each segment. Grey matter damage is also 
related to white matter changes (Audoin 2006, Chard 2002a), therefore the 
correlation between grey matter MTR decrease and change in NAWMF was 
also examined. Understanding progression in PPMS: Chapter 3     83   
 
3.1.3 Results 
3.1.3.1 Clinical changes  
Clinical changes over one year are summarized in Table 3.A. Patients 
progressed clinically with worsening EDSS scores (p=0.02). There was a non-
significant decrease in mean MSFC, with worsening of the TWT and NHPT 
scores. PASAT scores appeared to improve over one year. 
3.1.3.2. Predictive value of baseline MTR  
Lower MTR at baseline predicted greater clinical progression on both the EDSS 
and MSFC over one year after adjusting for age, gender and segmental atrophy 
(see Table 3.B). Baseline WB MTR (mean p=0.01, r -0.46) predicted change in 
EDSS. There was no contribution from lesion MTR, but NAWM MTR 
parameters predicted EDSS change (mean p=0.03, r -0.39 and PH p=0.04, r -
0.38). Baseline NAWM mean MTR below 37.0pu (this was chosen as a cut off 
because it was well below the lowest MTR value in controls, which was 
37.68pu) was able to predict worsening on the EDSS over one year with a 
specificity of 95%, sensitivity of 50%, positive predictive value of 83%, and 
negative predictive value of 79% (see Table 3.C). The overall accuracy of the 
test, indicating the proportion of correct predictions, was 80%. 
For the MSFC change the most complete predictor was the WB MTR (mean 
p=0.001, r 0.67; PH p=0.001, r 0.64; PL p=0.006, r 0.58). This prediction 
emerged largely from the NAWM segment (mean p<0.001, r 0.68; PH p<0.001, 
r 0.54). The grey matter MTR (PL p=0.02, r 0.51) and the lesion MTR (mean 
p=0.047, r 0.44; PL p=0.01, r 0.54) were weak predictors of MSFC change.  
Of the MSFC subtests, change in the zTWT was predicted by baseline NAWM 
(p<=0.001 in all cases, mean r 0.81, PH r 0.75, PL r 0.64) and grey matter 
parameters (PH p=0.007, r 0.55; PL p=0.004, r 0.58), and lesion MTR (mean 
p=0.01, r 0.52; PL p=0.009, r 0.53). zPASAT was weakly predicted by WB 
(mean and PH) and by lesion MTR (PL p=0.013, r 0.50). Although there was a 
group improvement in zPASAT, the positive correlation demonstrated that Understanding progression in PPMS: Chapter 3     84   
individuals with lower MTR values were more likely to have a lower zPASAT 
score after one year. 
 
Figure 3a: Baseline NAWM Mean MTR predicts change in EDSS over one 
year 
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NB The positive correlation is maintained when data are analyzed without the two 
outlying patients with EDSS change of +2 and +3 respectively (p=0.03, r -0.40). MTR= 
magnetization transfer ratio, NAWM=normal appearing white matter, EDSS=expanded 
disability status scale; pu=percent units 
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Table 3.B Baseline MTR parameters predict clinical change over one year 
 
MTR 
parameters at 
baseline 
Change in  
EDSS  MSFC  zPASAT  zNHPT  zTWT 
WB  M 
PH 
PL 
0.01  (-0.46) 
0.55   
0.07  (-0.34) 
0.001  (0.67) 
0.001  (0.64) 
0.006  (0.58) 
0.03  (0.43) 
0.03  (0.44) 
0.19 
0.18 
0.85 
0.08 
<0.001 (0.71) 
 0.001  (0.64) 
<0.001 (0.70) 
NAWM  M 
PH 
PL 
0.03  (-0.39) 
0.29 
0.04  (-0.38) 
0.001  (0.68) 
<0.001(0.54) 
0.68 
0.06 
0.10 
0.07 
0.26 
0.83 
0.20 
<0.001 (0.81) 
<0.001 (0.75) 
 0.001  (0.64) 
Grey 
matter 
M 
PH 
PL 
0.65 
0.72 
0.73 
0.11 
0.08 
0.02    (0.51) 
0.34 
0.57 
0.52 
0.60 
0.97 
0.190 
 0.06    (0.40) 
 0.007  (0.55) 
 0.004  (0.58) 
Lesion  M 
PH 
PL 
0.18 
0.12 
0.33 
0.047  (0.44) 
0.77 
0.01    (0.54) 
0.05  (0.40) 
0.66 
0.01  (0.50) 
0.69 
0.93 
0.82 
0.01     (0.52) 
0.74 
0.009   (0.53) 
 
P values are shown for each parameter, and significant p values (p<0.05) are shown in 
bold. They were obtained from multiple linear regression analysis with age, gender and 
intra-segmental volume as covariates where significant. R values, shown in brackets, 
were obtained from partial correlation coefficients. MTR= Magnetization transfer ratio, 
WB=Whole brain, NAWM=Normal appearing white matter. PH=Peak height, PL=Peak 
location. EDSS=Expanded disability status scale, MSFC=Multiple sclerosis functional 
composite, zPASAT=z-score for the Paced auditory serial addition test, zNHPT=z-
score for the Nine hole peg test, zTWT= z-score for the Timed walk test. Understanding progression in PPMS: Chapter 3     86   
 
Table 3.C Baseline NAWM mean MTR < 37 pu predicts worsening on EDSS 
over one year 
 
  NAWM mean 
MTR <37 pu 
 
NAWM mean 
MTR  >=37 pu 
TOTAL   
EDSS worsened  5 
 
5  10  Sensitivity 
50% 
EDSS the same 
or improved 
1  19  20  Specificity 
95% 
TOTAL 
 
6  24  30   
  Positive 
predictive 
value 83 % 
Negative 
predictive 
value 79% 
  Overall 
accuracy 
80% 
 
MTR= Magnetization transfer ratio, pu=percent units, NAWM=normal appearing white 
matter, < less than, >= greater than or equal to 
 
3.1.3.3. MRI changes over one year  
All mean MTR values decreased at one year in patients (see Table 3.D), with 
lesion MTR showing the least significant decrease (p=0.03), followed by NAWM 
(p=0.01). All peak location values, except for lesion MTR, decreased 
significantly (WB p=0.01, NAWM p=0.01, grey matter p=0.001), but only WB 
showed a significant decrease in peak height (p=0.03). In controls, there were 
no significant longitudinal changes in MTR. Significant differences in MTR 
change were only identified between patient and control groups in grey matter 
mean MTR (p=0.02).  
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Table 3.D MTR changes over one year in patients and controls 
 
 
MTR Parameter 
 
 
Baseline  
mean MTR 
(SD) 
 
One year 
mean MTR 
(SD) 
 
 
P 
value 
 
95% Confidence 
Interval 
Pts  vs 
cont  
(p 
value) 
Lower  Upper 
P
A
T
I
E
N
T
S
 
WB  M 
PH 
PL  
33.51 (1.43) 
0.98   (0.01) 
36.51 (1.23) 
33.20 (1.57) 
0.96   (0.01) 
36.13 (1.37) 
 
<0.001 
0.03 
0.01 
-0.45    
-0.0003  
-1.81      
 
-0.17 
-0.004 
-0.23 
- 
- 
- 
NAWM  M 
PH 
PL 
 
37.48 (1.46) 
0.19   (0.03) 
37.77 (1.03) 
 
37.24 (1.57) 
0.18   (0.03) 
37.56 (1.11) 
 
0.01 
0.15 
0.01 
 
-0.41    
-0.002     
-0.38  
 
-0.06 
0.013 
-0.05 
 
0.5 
0.6 
0.3 
 
Grey 
matter 
M 
PH 
PL 
 
31.31 (0.98) 
0.11   (0.01) 
32.64 (0.85) 
 
31.04 (1.03) 
0.10   (0.02) 
32.24 (0.91) 
 
<0.001 
0.50 
0.001 
 
-0.40    
-0.002  
-0.62    
 
-0.14 
0.004 
-0.18 
 
0.02 
0.4 
0.1 
Lesion  M 
PH 
PL 
 
31.38 (2.30) 
0.11   (0.03) 
34.23 (2.28) 
31.05 (2.38) 
0.12   (0.04) 
33.75 (2.28) 
0.03 
0.18 
0.09 
-0.61  
-0.025  
-1.03  
-0.03 
0.005 
0.08 
- 
- 
- 
C
O
N
T
R
O
L
S
 
WB  M 
PH 
PL 
 
34.72 (0.38) 
0.01   (0.009) 
37.42 (0.45) 
34.72 (0.64) 
0.01   (0.01) 
37.09 (0.78) 
0.20 
0.36 
0.36 
-0.25     
-0.002       
-0.70  
0.25 
0.001 
0.05 
- 
- 
- 
NWM  M 
PH 
PL 
 
38.40 (0.40) 
0.20   (0.02) 
38.51 (0.37) 
 
38.23 (0.57) 
0.20   (0.02) 
38.40 (0.53) 
 
0.99 
0.41 
0.09 
-0.44    
-0.003      
-0.37     
0.10 
0.01 
0.15 
- 
- 
- 
Grey 
matter 
M 
PH 
PL 
 
32.90 (0.44) 
0.12   (0.01) 
33.13 (0.56) 
 
32.28 (0.68) 
0.12   (0.02) 
33.09 (0.74) 
 
0.89 
0.49 
0.73 
-0.27     
-0.006      
-0.34    
0.23 
0.003 
0.24 
- 
- 
- 
Mean and Peak location MTR values are in percent units, and Peak height is given in 
percent volume. Pts vs cont = changes in patients compared to controls. Significant p 
values (p<0.05) are shown in bold, and are derived from paired t-tests for in-group 
comparisons, and multiple linear regression adjusting for age and gender for between- 
group comparisons. MTR=magnetization transfer ratio, WB=whole brain, 
NAWM=normal appearing white matter, NWM= normal white matter, M=Mean, 
PH=peak height, PL=peak location.  Understanding progression in PPMS: Chapter 3     88   
3.1.3.4. Correlations between MTR and volume changes  
Correlations were found between decrease in WB, grey and NAWM peak height 
MTR and decrease in corresponding intra-segmental volume (p=0.01, p=0.008, 
p<0.001 respectively, see Table 3.E). Change in NAWM mean and peak 
location MTR parameters also correlated significantly with the progression of 
atrophy in corresponding brain tissues (p=0.03 in both cases). There was no 
significant correlation between the grey matter MTR decrease and change in 
NAWMF. 
 
Table 3.E Correlation of change in MTR with change in segmental volume 
over one year 
Changing MTR 
parameter 
 
Correlation with segmental volume change 
p value  r value  r² 
WB  Mean  0.15  0.3  0.08 
PH  0.01  0.47  0.23 
PL  0.10  0.32  0.10 
NAWM  Mean  0.03  0.42  0.18 
PH  0.008**  0.50  0.24 
PL  0.03  0.42  0.17 
Grey 
matter 
Mean  0.61  0.10  0.01 
PH  <0.001**  0.67  0.45 
PL  0.21  0.24  0.06 
 
P values are derived from Pearson’s test. Significant values at p<0.05 are shown in 
bold  and  at  p<0.01  with  asterisks  **.  Mean  and  Peak  location  MTR  values  are  in 
percent units, and Peak height is given in percent volume. MTR=Magnetization transfer 
ratio,  WB=Whole  brain,  NAWM=Normal  appearing  white  matter.  PH=Peak  height, 
PL=Peak location. r= correlation coefficient for Pearson’s test. 
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3.1.4 Discussion 
3.1.4.1 MTR parameters predict clinical change  
This study shows, for the first time, that brain MTI is a modest predictor of 
clinical evolution in PPMS, over a relatively short period. Importantly, 
predictions survived adjustment for segmental volume, demonstrating that the 
predictive value of MTI is independent of atrophy. However, over a short study 
period clinical and imaging changes are necessarily small, and longer follow-up 
is necessary to investigate the role of MTI as a prognostic indicator (see section 
3.2). 
Over one year EDSS scores deteriorated significantly, but MSFC decline was 
not statistically significant. This may be explained by several factors. Firstly, 
MSFC data was not available on all patients. Secondly, mean zTWT and 
zNHPT scores declined over one year, but zPASAT scores improved. This was 
probably due to practice effects and a reduced anxiety, as patients became 
accustomed to testing (Tombaugh 2006, Solari 2005). Lastly, patients unable to 
complete the TWT at baseline could not demonstrate further reductions in 
mobility on the MSFC, whereas their EDSS score increased. Nevertheless, the 
MSFC may provide useful information in this study. It has been shown to be 
more accurate than the EDSS for detecting group differences within a sample in 
cross-sectional studies (Hobart 2004). There is evidence that the two scales do 
not correlate well, and thus may provide complementary clinical information 
(Kragt 2008). Indeed, in our study, reduction in zTWT sub-scores was more 
strongly predicted by imaging parameters than any other clinical test. This 
emphasizes that decreasing mobility is likely to be a prime indicator of 
progression in this cohort, in which 23 out of 30 patients presented with a 
spastic paraparesis.  
NAWM MTR parameters appear to be driving the prediction of clinical change. 
Only NAWM peak height did not predict EDSS change; significance was lost 
after adjustment for baseline brain volume. We identified the NAWM mean MTR 
with a cut-off value of 37pu as the best indicator of progression in this sample. 
The overall sensitivity for predicting progression was 50%, with a specificity of 
95%; using a higher cut-off value increased sensitivity, but decreased Understanding progression in PPMS: Chapter 3     90   
specificity. The value provides information at a group level for this cohort. 
However, in order to validate a specific predictive MTR value for clinical use, to 
predict disability in individuals with PPMS, much larger studies would be 
necessary. Such a value would be scanner- and sequence-specific (see section 
2.8.2.2). 
Regarding the other MTR parameters, lesion MTR also predicted decline in 
MSFC, but not EDSS. Baseline grey matter MTR was only a weak predictor of 
MSFC change; possible reasons for this are discussed in section 3.1.4.2. 
3.1.4.2 MTR decreases significantly over one year  
To our knowledge only one previous study evaluated MTR in longitudinal follow-
up of PPMS (Filippi 2000b): no significant change in lesion, WB or NABT MTR 
was found in nine PPMS patients over one year. Median disease duration in the 
PPMS group was 8 years, with a range of 3-14 years.  
In our patients grey matter MTR decreased significantly, but the decrease in 
NAWM MTR was less notable. Similar results were obtained in a diffusion 
tensor study in advanced PPMS (mean disease duration 10 years), which 
observed marked deterioration in grey matter indices over a year, without 
significant NAWM change (Rovaris 2005). Furthermore, relatively marked grey 
matter MTR decline has been identified in early RRMS (Davies 2005), while CIS 
patients have shown equivalent reduction in grey and white matter MTR 
(Fernando 2005). In this study, the relatively extensive changes in grey 
compared to NAWM MTR could be due to grey matter lesion accumulation. 
Lesions within the cortex and deep grey matter are very extensive in 
progressive MS (Bruck 2005, Kutzelnigg 2005a, Kidd 1999), and can not be 
reliably detected on conventional MRI scans even at higher field strengths 
(Geurts 2005a). The grey matter thus contained an unknown number of lesions, 
while visible white matter lesions were masked out of the analysis. The role of 
partial volume effects, as discussed in section 3.1.1, should also be considered 
when interpreting the decline in grey matter MTR. Grey matter atrophy without 
significant white matter atrophy is known to have developed in this cohort over 
one year (Sastre-Garriga 2005a), and as brain volume decreases, there is an 
increase in the number of outer voxels at the brain/CSF interface. However, Understanding progression in PPMS: Chapter 3     91   
steps were taken to minimize this effect. Two outer voxel erosions were carried 
out for the white matter, and one for the grey matter, discarding voxels with an 
MTR value below 10pu. MTR histograms were then normalised for brain 
volume. Furthermore, when we correlated atrophy and MTR changes, only the 
grey matter peak height showed a relationship with atrophy. There were no 
significant correlations with grey matter mean and peak location, where the 
significant longitudinal MTR reductions occurred.  
Finally, although grey matter MTR decreased more than NAWM MTR over the 
study, NAWM MTR was a better baseline predictor of clinical change. This may 
suggest an imbalance of changes in each segment prior to the start of the 
study: if NAWM changes occurred earlier in the disease course, they would 
initially contribute more to the clinical picture. Davies and colleagues, studying 
MTR in RRMS patients, extrapolated their findings backward, suggesting that 
NAWM changes had begun prior to symptom onset (Davies 2005). If NAWM 
changes preceded grey matter changes in our cohort, we would expect the grey 
matter changes evident in this study to affect clinical outcome in subsequent 
years (see section 3.2). This has been demonstrated in a DTI study in 
established PPMS (mean disease duration 10 years), in which grey matter 
damage predicted disability at five years (Rovaris 2006). In other MS subtypes, 
grey matter MTR has predicted long term EDSS progression over 8 years 
(Agosta 2006).  
3.1.4.3 MTR changes and progression of atrophy  
Weak to moderate correlations emerged between MTR and volume changes 
over one year. Decrease in peak height MTR was most strongly associated with 
the development of segmental atrophy, confirming previous findings (Rovaris 
1999, Phillips 1998). An increase in low MTR voxels widens and flattens the 
normalized histogram (Tofts 2004). Statistically, however, atrophy explained 
less than 10% of the significant decrease in grey matter MTR, and less than 
20% of the decrease in NAWM MTR.  
Our results emphasize that there is a modest relationship between atrophy and 
MTR, and that in patients with PPMS MTR measures must be interpreted in the 
context of atrophy. However, we have shown that MTR is an independent Understanding progression in PPMS: Chapter 3     92   
marker of pathology. Significant MTR changes were not explained by brain 
volume changes, and baseline MTR predicted progression independently of 
atrophy. 
 
3.2 Monitoring and predicting clinical progression over three 
years in early PPMS 
3.2.1 Introduction 
It has been demonstrated that MTR reduction in the NABT correlates with 
disability in early PPMS (Ramio-Torrenta 2006). In section 3.1, we showed that 
baseline NAWM MTR predicts short-term clinical progression, and that MTR is 
sensitive to short-term brain tissue changes. This data implies that MTR may be 
a useful measure not only to improve understanding of disease progression in 
PPMS, but also to predict and monitor progression in a clinical setting.  
A number of clinical challenges stem from the wide variation in the evolution of 
disability among individuals with PPMS (Tremlett 2005). The absence of 
predictive markers for clinical outcome has adversely affected clinical trials, 
such as the glatiramer acetate study in PPMS, which was terminated early 
because patients did not progress as anticipated (Wolinsky 2007). In addition, 
robust surrogate markers are needed to detect treatment effects (Johnston 
2007). The potential for using MRI surrogate markers in MS was explored by a 
working group in 1999 (McFarland 2002), and they adopted criteria described 
by Prentice (Prentice 1989). These state that a surrogate marker should predict 
future clinical disability, and that any intervention must alter both the surrogate 
marker and clinical outcome by the same mechanism. In establishing these 
criteria, the requirement that the marker should change concurrently with clinical 
status was not included. However, this attribute is clearly advantageous 
because it allows monitoring of contemporaneous, as well as future, treatment 
effects.  
In this study we examined the potential of MTR as a surrogate marker to 
monitor progression in early PPMS in a medium term study suited to clinical trial 
design. For this purpose, we compared MTR to conventional MRI markers Understanding progression in PPMS: Chapter 3     93   
which have been more widely used as outcome measures in MS clinical trials: 
T2 lesion load and atrophy. First, we assessed whether changes over three 
years in MTR, brain volume or T2 lesion load reflected concurrent clinical 
changes. Secondly we explored whether baseline MTR was a better predictor of 
clinical progression compared to the other two MR measures.  
3.2.2 Methods 
3.2.2.1 Subjects 
As described in study 3.1, 50 patients with definite or probable PPMS 
(Thompson 2000), within five years of symptom onset, were invited for 
radiological assessment at baseline. Following this, they were assessed six 
monthly for three years, and at each time-point they were scored on the EDSS. 
As before, two patients were excluded after baseline: one developed 
claustrophobia and one withdrew, and a third patient was excluded because all 
images were of sub-optimal quality (see section 3.2.2.3). The patient who did 
not complete the baseline protocol and was excluded from study 3.1 attended 
all other time-points and was therefore retained in this study. Thus the total 
number of patients was 47 (Table 3.F). Clinical data was obtained in person or 
by telephone (Lechner-Scott 2003) for patients who became too disabled to 
undergo scanning during the study, including those with severe ataxia 
preventing them from lying still, and those who were unwilling to attend the 
centre (Table 3.G). Two patients died of conditions unrelated to MS during the 
study and were excluded from subsequent analysis, one withdrew, and one was 
unwell at the final time-point. Thus 43 patients were assessed at three years 
(Table 3.G). None of the patients were taking disease modifying medications. 
One patient had a single course of intravenous (iv) steroids for a deterioration of 
symptoms, and two patients were taking regular courses of oral steroids every 
three months. 
Eighteen healthy controls (see Table 3.F), a different group from the controls in 
study 3.1, underwent the same scanning protocol. Adjustments for age and 
gender differences between the patient and control group were made at each 
stage of the analysis, as described below.  
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Table 3.F Baseline clinical and imaging characteristics of patients and 
controls 
  Patients  Controls  p value 
Mean age in years (range)  45.1 (19-65)  34.6 (27-52)  <0.001 
Gender (male/female)  28/19  8/10  0.08 
Median EDSS (range)  4.75 (1.5-7)  -  - 
Mean T2 lesion load (ml)  30.3  -  - 
Mean grey matter volume  
(SD; mean PGMF [%]) 
710.4 
(78.6;47.7) 
726.4 
(70.6;49.7) 
0.001 
Mean NAWM volume                   
(SD; mean PNAWMF [%]) 
369.2 
(50.5;24.8) 
395.5 
(38.3;27.0) 
<0.001 
 
Grey matter 
MTR 
Mean (SD) 
PH, mean (SD) 
PL, mean (SD) 
31.8 (1.1) 
10.0 (1.4) 
33.3 (0.6) 
33.1 (0.4) 
12.1 (1.0) 
33.8 (0.5) 
<0.001 
<0.001 
0.006 
 
NAWM MTR 
 
Mean (SD) 
PH, mean (SD) 
PL, mean (SD) 
37.2 (0.9) 
17.4 (2.7) 
37.7 (0.8) 
38.1 (0.5) 
20.2 (1.5) 
38.4 (0.5) 
<0.001 
<0.001 
0.001 
 
EDSS= Expanded disability status scale, SD=Standard deviation, PGMF=Percentage 
grey matter fraction, PNAWMF=Percentage normal appearing white matter fraction, 
NAWM=Normal appearing white matter, MTR=Magnetization transfer ratio, PH=Peak 
height,PL=Peak location, pu=Percent units . PH is given in percent volume, and mean 
and PL in percent units. P values were derived from unpaired 2 tailed t-tests for patient 
versus control variables.  Understanding progression in PPMS: Chapter 3     95   
 
Table 3.G Numbers of patients assessed at each time-point and reasons 
for non-attendance 
Time-point (months)  0  6  12  18  24  30  36 
Total patients assessed:  47 
 
37  36  33  34  30  43 
Scan performed   46 
 
34  33  33  30  25  37 
Clinical assessment only, done in person 
 
1  3  3  0  3  2  2 
Clinical assessment only, done by telephone 
 
0  0  0  0  1  3  4 
Patients who did not attend:  0 
 
10  11  14  13  17  4 
Withdrew from study  0 
 
0  0  0  0  1  1 
Personal commitments  0 
 
7  6  7  5  7  0 
Non-MS related illness  0 
 
3  2  3  4  6  1 
Upgrade  0 
 
0  2  3  3  2  0 
Death  0 
 
0  1  1  1  1  2 
 
Clinical assessment only= Patients too disabled to be scanned, including patients with 
severe ataxia preventing them from lying still. Personal commitments= patient unable 
to attend within time allocated due to existing commitments. Upgrade= time-point 
missed because scanner was being upgraded.  
 
3.2.2.2 MRI Acquisition  
All scans were performed on a 1.5 Tesla scanner (General Electric Co, 
Milwaukee, Wisconsin, USA). Each time-point was separated by a mean of 26.7 Understanding progression in PPMS: Chapter 3     96   
weeks (range 25.3-29.0 weeks). The scanner was upgraded during the study, 
and the gradient amplifiers, but not the gradient coils, were changed. Maximum 
gradient strength increased from 22mTm
-1 (milli-Tesla per metre) to 33mTm
-1. 
The scanner software was upgraded from SIGNA version 5x to version11x. The 
upgrade was accounted for at each stage of the statistical analysis (see below).  
Subjects underwent brain MTI (Barker 1996), producing inherently co-registered 
proton density- (PD) and T2-weighted images (see 3.1.2.2); MTI parameters 
were unchanged after the upgrade. 3D inversion-prepared fast spoiled gradient 
recall (3D FSPGR) volume sequences of the brain were also acquired (see 
3.1.2.2), and the FSPGR repetition time was reduced from 13.3 to 10.9 ms after 
the upgrade. 
3.2.2.3 Post-processing 
Images were displayed on a Sun workstation (Sun Microsystems, Mountain 
View, CA) using DispImage software (DispImage, D. Plummer, Department of 
Medical Physics and Bioengineering, UCL, UK).  
In this study more accurate segmentation was achieved than in study 3.1, using 
the FSPGR images acquired during the same session as the MT, on which the 
boundary between grey and white matter was more clearly defined. 
Segmentation was carried out in SPM2, using a maximum likelihood algorithm. 
This assigns voxels to grey matter, white matter, or CSF segments according to 
spatial prior probabilities, ascertained here by reference to a standard a priori 
tissue probability map, and voxel signal intensity. This time we dealt with the 
problem of partial volume voxels by introducing a threshold of 0.75 to the 
NAWM and grey matter segments (Smith 2006), so that only voxels with a 75% 
or greater likelihood of being situated in each respective segment were included 
there. This ensured that voxels with any appreciable partial volume were 
excluded, wherever they were situated. Erosions would have reduced the 
volume of tissue retained in the analysis, and unnecessarily excluded full 
volume voxels situated in the eroded layer. This method also kept the 
segmentation process completely separate from the generation of MTR values, 
because the MTR value obtained had no relevance in determining the 
boundaries of the map (Tofts 2004). Understanding progression in PPMS: Chapter 3     97   
The FSPGR was co-registered to the PD MTR image (Mo), and the 
transformation parameters were applied to grey and white matter probability 
maps. In patients, T2 lesions were contoured and converted into binary lesion 
masks, as described in section 3.1.2.3.1 Segmentation was carried out in 
SPM2, and the lesion masks applied to the FSPGR images to generate grey, 
NAWM and lesion segment probability maps. The volume of each tissue 
segment was calculated in SPM2. Raw grey and NAWM brain volumes were 
normalized by dividing them by the total intracranial volume (the sum of the grey 
matter, NAWM, lesion and CSF volumes), and multiplying by 100 to produce a 
percentage grey and NAWM fraction (PGMF and PNAWMF).  
The voxel MTR was calculated, and the probability maps applied to produce 
grey, NAWM and lesion MTR maps as described in section 3.1.2.3.1. One 
patient demonstrated severe movement artefacts on every MT image, and was 
excluded from the study. Histograms, normalized to the segment volume (bin 
width 0.1pu, smoothing window 0.3pu), were generated for the grey and 
NAWM, and the mean, peak height (PH) and peak location (PL) were obtained. 
The lesion segment was considered too small to create acceptable histograms, 
and only mean MTR was measured. In controls, the procedure was the same 
without the application of a lesion mask.  
3.2.2.4 Statistical Analysis  
Analysis was carried out using Stata 9.2 (Stata Corporation, Texas, USA).  
3.2.2.4.1 Clinical data  
Raw EDSS scores at baseline and three years were compared using the 
Wilcoxon matched-pairs signed-ranks test. Changes in EDSS were converted 
into steps (see section 3.1.2.4.1). For predictors of clinical outcome, three step 
change categories were created: stable EDSS, mild progression (EDSS 
deterioration of 0.5-1.5 steps), and marked progression (deterioration of 2 steps 
or more).  
 
3.2.2.4.2 Piecewise mixed effect linear regression models 
These models are standard linear mixed models, also known as multilevel or 
hierarchical regression models (Verbeke and Molenberghs 2000, Goldstein H Understanding progression in PPMS: Chapter 3     98   
1995), but we adapted them specifically to adjust for the scanner upgrade. A 
simple linear regression with time as predictor would ignore the fact that 
different data points may belong to the same subject, and estimate a single 
residual variance around one fitted line. In contrast, linear mixed models 
accommodate the two-level structure of the data by estimating two components 
of variance: within-subject variation (around individual subject trajectories) and 
between-subject variation (in intercept and in rate of change with time). In the 
absence of upgrade the rate of change of the response variable over time is 
given directly by the coefficient on time. Non-linearity can be examined by fitting 
an additional quadratic term in time.   
 
To adjust for the upgrade, a modification of the linear mixed model is necessary 
to make it ‘piecewise’: instead of one continuous trajectory being fitted, two 
separate trajectories, with common gradient, are fitted before and after the 
upgrade, but estimated simultaneously within one model. The assumption of 
common gradient is tested, and if there is no evidence for a gradient change the 
common gradient in the piecewise model gives the rate of change adjusting out 
the discontinuity due to upgrade. 
 
Linear mixed models allow the inclusion of all available data points in the 
analysis, so that subjects with some data points missing still contribute 
information. This minimizes bias that could result from the exclusion of these 
subjects, for example from a method that examined change over just two time 
points. Another advantage particular to the piecewise adaptation is that both 
sections of the data, before and after the upgrade, contribute to the estimation 
of the single underlying adjusted rate of change. Separate regression before 
and after would not achieve this formally, and would not allow the assumption of 
a common gradient to be tested.  
 
3.2.2.4.3 Rates of change in brain MTR, volume and T2 lesion load 
For the following analyses, except for those predicting EDSS outcome, 
piecewise mixed effect linear regression models were fitted. The models used 
random intercept and random time coefficient. The models assume that the 
changes are linear. We tested for non-linearity in the data by adding a quadratic 
term in time, and none was found.  Understanding progression in PPMS: Chapter 3     99   
 
To determine mean annual rates of MTR change in patients versus controls, 
mean, PH and PL for grey and NAWM MTR were modelled in turn as response 
variables. The covariates were: a binary upgrade indicator, time (centred on the 
upgrade date to adjust for a scanner upgrade effect), a patient/control indicator, 
patient*time interaction, age and gender. The mean annual rate of lesion MTR 
change in patients was calculated in the same way, without the patient/control 
indicator. For brain volume changes, age was a significant covariate so an 
age*time interaction was added. The model was repeated using PGMF and 
PNAWMF. In patients, lesion load changes were similarly modelled, with an 
age*time interaction but without the patient/control indicator. To assess the 
relationship with change in EDSS in patients, the same MTR and volume 
variables were modelled in turn as response variables, and clinical change and 
clinical change*time were additional covariates.  
 
3.2.2.4.4 Baseline MRI predictors of EDSS change 
Multiple proportional odds ordinal logistic regression was used. Ordinal 
categories of EDSS step change were the response variable, and baseline MTR 
and volume parameters, age and gender were the covariates. Predictors were 
modelled individually, then the most significant predictor from each modality 
was selected for each segment (grey, NAWM and lesions). These were then 
modelled together to identify the best overall predictor. All baseline scans were 
performed before the upgrade so no adjustment was necessary. Understanding progression in PPMS: Chapter 3     100   
3.2.3 Results 
The results are summarized in Table 3.H 
3.2.3.1 Changes in EDSS and MRI parameters over three years  
Median EDSS scores increased from 4.5 to 6 (p<0.001). Fourteen patients 
remained stable, 14 demonstrated mild and 15 marked progression. In patients, 
grey matter mean MTR declined by -0.60pu and NAWM mean MTR by -0.26pu 
(p<0.001 in both cases). Annual changes in grey and NAWM MTR parameters 
for patients and controls are shown in Table 3.I. Lesion MTR increased by 
0.77pu, at a rate of 0.26pu per year (p=0.002, 95%CI 0.09 to 0.42). 
In patients, mean grey matter volume decreased by -12.0ml, at an annual rate 
of -3.98ml, 0.26% of the original grey matter fraction (p<0.001, 95%CI -5.82 to -
2.15). NAWM volume decreased by -0.77ml per year, which was not significant. 
T2 lesion volume increased annually by 2.80ml, or 9.25% of the original T2 
volume (p<0.001, 95%CI 1.87 to 3.74). In controls, there were no significant 
changes. The rate of change in PGMF (percentage grey matter fraction; 
p=0.005) but not PNAWMF (p=0.47) was significantly different between patients 
and controls. 
 
Table 3.H Summary of significant findings for MTR, volume and lesion 
load measurements in early PPMS 
  MTR decrease  Volume decrease  T2 lesion 
load 
increase 
Grey 
matter 
NAWM  Grey 
matter 
NAWM 
Longitudinal changes    
Yes 
 
Yes 
 
Yes 
 
No 
 
Yes 
Rate of change correlates 
with EDSS changes 
 
Yes 
 
No 
 
No 
 
No 
 
Yes 
Baseline measure predicts 
future clinical progression 
 
Yes** 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
NAWM=Normal appearing white matter. MTR=Magnetization transfer ratio. EDSS= 
Expanded disability status scale. ** Baseline grey matter PH MTR was the strongest 
predictor of deterioration. Understanding progression in PPMS: Chapter 3     101   
 
Table 3.I Mean annual rates of change in grey and NAWM MTR in patients 
and controls 
 
MTR=Magnetization transfer ratio, pu=Percent units. 95%CI=95% confidence intervals. 
PH=Peak height, PL=Peak location. p values derived from piecewise mixed effect 
linear regression models. PH is given in percent volume, and mean and PL in percent 
units. MTR changes in controls were not statistically significant. 
 
MTR 
Histogram 
parameter 
 
PATIENTS 
 
CONTROLS 
Patients 
versus 
controls 
Yearly rate 
(p value)  
 
95%CI 
Yearly rate 
(p value) 
 
95%CI 
 
P value 
Grey 
Matter 
Mean  - 0.20 
(<0.001) 
-0.25 to -0.15  0.02 
(0.62) 
-0.05 to 0.08  <0.001 
PH  - 0.12 
(0.03) 
-0.23 to -0.01  -0.06 
(0.31) 
-0.19 to 0.56  0.41 
PL  - 0.10 
(0.007) 
-0.17 to -0.03  0.02 
(0.58) 
-0.06 to 0.10  0.01 
NAWM  Mean  - 0.09 
(<0.001) 
-0.12 to -0.05  0.002 
(0.90) 
-0.34 to 0.40  <0.001 
PH  - 0.17 
(0.14) 
-0.40 to 0.05  -0.06 
(0.63) 
-0.29 to 0.18  0.42 
PL  - 0.07 
(0.003) 
-0.13 to -0.03  -0.0006 
(0.98) 
-0.56 to 0.55  0.02 Understanding progression in PPMS: Chapter 3     102   
 
3.2.3.2 Surrogate MRI markers of clinical change 
3.2.3.2.1 Markers of concurrent clinical progression 
In the grey matter, rapid mean MTR decrease was associated with greater rates 
of EDSS progression (there was a 0.04pu greater annual MTR decline for each 
EDSS step deterioration, p=0.03, 95%CI -0.82 to -0.003, see Figure 3b), as was 
PL MTR (0.07pu greater annual MTR decline for each EDSS step deterioration, 
p=0.008, 95%CI -0.01 to -0.2), but not PH MTR decrease. NAWM and lesion 
changes were not associated with progression rate.  
 
Volume changes in grey and NAWM were not associated with the rate of EDSS 
change. Greater rate of T2 lesion load increase was associated with faster 
progression on EDSS (lesion volume increase of 0.70 ml for each EDSS step 
deterioration, p=0.02, 95% CI 0.09 to 1.31). 
3.2.3.2.2 Baseline predictors of clinical progression 
Lower baseline grey matter mean MTR (odds ratio [OR] 2.34, p=0.02, 95%CI 
1.18 to 4.76; see Figure 3c) and lower grey matter PH MTR (OR 2.43, p=0.008, 
95%CI 1.27 to 4.65) predicted worse outcome on the EDSS. Grey matter PL 
MTR showed a trend towards prediction (p=0.09). Lower NAWM PL MTR 
predicted worse outcome on the EDSS (OR=2.5, p=0.04, 95%CI 1.04 to 5.88) 
and NAWM PH MTR showed a trend (p=0.09). Lower baseline PGMF (OR 1.42, 
p=0.04, 95%CI 1.01 to 2.00), lower baseline PNAWMF (OR 1.36, p=0.03, 
95%CI 1.03 to 1.80), and greater T2 lesion load (OR 1.03, p=0.02, 95%CI 1.00 
to 1.06) were also predictors of worse outcome on EDSS. When the most 
significant univariate predictors from each modality and segment were modelled 
together, only grey matter PH MTR remained significant (OR 2.9, p=0.04, 
95%CI 1.06 to 8.17).  Understanding progression in PPMS: Chapter 3     103   
 
Figure 3b: Grey matter mean MTR decline by EDSS step change over 
three years 
 
 
The three lines represent patients who are stable over three years, patients with an 
overall EDSS step deterioration of 1, and patients with an overall step deterioration of 2 
over three years. Those with a more rapid EDSS decline have a faster rate of MTR 
reduction. The model predicts MTR decline over time centred on the upgrade, at 
time=0 (see section 3.2.2.4.2 for details); the initial time-point for each patient occurs 
up to three years earlier. The model is adjusted for age, gender and upgrade. EDSS= 
Expanded disability status scale, MTR=Magnetization transfer ratio, pu=Percent units  Understanding progression in PPMS: Chapter 3     104   
Figure 3c Grey matter mean MTR (A) and grey matter PH MTR (B) at 
baseline, in patients who remained stable and patients who progressed 
markedly over 3 years                                                 
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PL showed only a trend to prediction and is therefore not represented. The boxes 
represent the values between the 25
th and 75
th centile. The horizontal line within the 
box represents the median. The vertical lines attached to the box represent adjacent 
values, and the small circles represent outside values. MTR=Magnetization transfer 
ratio, PH=Peak height. Understanding progression in PPMS: Chapter 3     105   
3.2.4 Discussion 
We found MTR decline, particularly in the grey matter, grey matter atrophy, and 
increasing T2 lesion load over three years in early PPMS. The rate of change in 
grey matter MTR and T2 lesion load, but not grey matter volume, reflected the 
rate of clinical deterioration. Baseline MTR, brain volume and T2 lesion load 
predicted clinical progression, and grey matter PH MTR emerged as the 
strongest predictor.  
3.2.4.1 MRI changes 
The disproportionate evolution of grey matter damage, measured using MTR 
and atrophy, was already evident at one year in subgroup of this cohort (see 
section 3.1, and Sastre-Garriga 2004) and has been identified in other MS 
subtypes (Horakova 2007, Valsasina 2005). Cortical lesions may account for 
the majority of this injury. They exhibit demyelination, contain apoptotic neurons 
(Rovaris 2005, Valsasina 2005, Peterson 2001) and have been associated with 
axonal transection and loss (Dutta 2007). Wallerian degeneration secondary to 
axonal damage from white matter inflammation (Brownell 1962) may also 
reduce grey matter MTR and tissue volume. Conversely, the imaging 
techniques we used could be less sensitive to processes involved in NAWM 
damage. For example, inflammatory processes may mask NAWM atrophy 
(Pirko 2007, Kutzelnigg 2005b). This is less likely in the grey matter, because 
cortical lesions are less inflammatory (Pirko 2007, Peterson 2001). Notably, the 
relatively small decline in NAWM MTR is not explained by the removal of the 
white matter lesions, regarded as the main focus of white matter injury: lesions 
showed an overall increase in MTR. This is possibly due to remyelination, which 
has been demonstrated in pathological studies in PPMS of longer disease 
duration (Patrikios 2006); our results suggest that lesion remyelination may also 
be a feature in the early phase of PPMS.  
3.2.4.2 Predicting progression 
From a clinical perspective, grey matter MTR changes were the most relevant. 
In the sub-group of this cohort studied at one year (see section3.1), there was a 
stronger association between NAWM MTR and EDSS change; grey matter 
MTR predicted timed walk test changes only. In contrast, at three years grey Understanding progression in PPMS: Chapter 3     106   
matter MTR is the stronger predictor of EDSS change. This suggests that the 
role of NAWM pathology in determining disease progression may be decreasing 
over time.  
Regarding the grey matter MTR histogram parameters, an 8 year follow-up 
study in different MS subtypes also identified grey matter peak height MTR as a 
predictor of clinical disability (Agosta 2006). However, the importance of a 
specific MTR parameter should not be over-emphasized: each one describes 
only a single point of the histogram (Zhou 2004). In this study, changes in two 
grey matter parameters (mean and PL MTR) were significantly correlated with 
the rate of clinical progression, and two predicted disability (baseline mean and 
PH MTR). This highlights the importance of viewing parameters as a group 
when evaluating pathological changes and their clinical significance, rather than 
concentrating on a single measure (see section 2.8.4.2). 
3.2.4.3 Monitoring progression 
Our findings advocate grey matter MTR as a possible surrogate marker of 
progression in PPMS. It was the strongest predictor of future disability and 
changed contemporaneously with clinical status. In addition, treatments shown 
to counteract MTR reduction could be explained as reducing demyelination and 
axonal loss, the substrates of progression (Pirko 2007, Schmierer 2004), thus 
addressing a further criterion for a surrogate marker. However, evidence from a 
single natural history study can only promote grey matter MTR as an un-
validated surrogate (McFarland 2002); larger natural history studies exploring 
MTR changes in PPMS, and more data on the effect of MS therapies on MTR 
are required (Filippi 2007). Finally, there are practical challenges to 
implementing MTR as a surrogate marker in multi-centre studies. A 
standardized MTR sequence applicable to scanners from different 
manufacturers has been proposed, although it was only reproducible within 2.5 
pu between sites (Barker 2005). However, further improvements are possible 
using dedicated research scanners with careful attention to the flip angle, B1 
calibration and patient positioning, and with the use of body coil excitation (Tofts 
2004).  Understanding progression in PPMS: Chapter 3     107   
Our findings also suggest that T2 lesion load is a potential surrogate, as has 
been the case in other MS subtypes (Rovaris 2003). To reflect both focal white 
matter injury and diffuse neurodegenerative change, a combination of grey 
matter MTR and T2 lesion load may be optimal (Rovaris 2003). However, our 
combined model suggests that T2 lesion load is a weaker predictor than grey 
matter MTR in this group. Perhaps surprisingly, a study in other MS subtypes, in 
a less disabled patient group, also identified grey matter MTR as being a 
stronger predictor of worsening than T2 lesion load (Agosta 2006). In contrast, 
developing brain atrophy, regarded as a potential surrogate marker in 
established PPMS (Fazekas 2007, Simon 2001), did not reflect concurrent 
clinical change in this group. This may reflect a delay between demyelination 
and axonal loss, the development of associated atrophy, and the clinical 
consequences of the tissue loss. Indeed, clinical trials utilizing brain volume as 
a surrogate have required extensive follow-up to demonstrate treatment effects 
(Simon 2006), and in advanced PPMS brain atrophy predicted clinical outcome 
five years later, but not before (Sastre-Garriga 2005b, Ingle 2002).  
 
3.2.4.4 Limitations 
The main limitation of this study was incomplete attendance, particularly relating 
to worsening disability which prevented us from scanning the patients with 
higher EDSS scores. This is an inevitable problem in longitudinal studies of 
disabling conditions. We were able to address this by using a statistical model 
which minimized bias due to drop-out by utilizing all available data at each time-
point, so that subjects who missed time-points still contributed to the gradient.  
The second limitation was the scanner upgrade. After the upgrade, changes to 
the acquisition parameters were minimized, but one parameter was changed 
(see 3.2.2.2). Using the piecewise mixed effects model, we were able to take 
the upgrade into account, and in effect “edit out” discontinuity caused by the 
upgrade from the trajectory of change, making the longitudinal correlations 
more robust. In addition, all the changes in patients are described with 
reference to controls scanned both before and after the upgrade. These 
approaches address a common problem in longitudinal MR studies, which is 
particularly relevant for the investigation of quantitative MR measurements.  Understanding progression in PPMS: Chapter 3     108   
3.3 Conclusions 
MTR histogram analysis is a sensitive measure for detecting change in brain 
tissues over a relatively short period in PPMS. MTR measures are able to 
predict short and medium term progression, and grey matter MTR parameters 
decline concurrently with clinical ability. The evident potential for MTR to satisfy 
the criteria for a surrogate marker of progression in early PPMS could be 
investigated in larger studies including natural history observations and 
therapeutic trials. 
Our results suggest that NAWM MTR is more clinically relevant in the early 
stages in this patient group. As the disease advances, grey matter MTR 
becomes more closely related to progression, perhaps indicating that grey 
matter pathology is now driving disability. Lesion MTR loses its clinical 
relevance over time, perhaps due to lesion heterogeneity and remyelination.  
Finally, while grey matter MTR is the strongest clinical predictor at three years, 
T2 lesion load remains extremely relevant to clinical outcome. This indicates 
that focal white matter inflammation also plays an important role in determining 
disability in early PPMS. Further follow-up of this group will be interesting to 
determine whether the influence of T2 lesion load declines over time, as has 
been demonstrated previously in established PPMS (Khaleeli 2008). The impact 
of white matter lesions in PPMS is explored further in Chapter 5. Understanding progression in PPMS: Chapter 3     109   
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Localizing tissue injury: 
Voxel-based Analysis of MTR and 
Atrophy 
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4.1 Introduction 
 
In Chapter 3 we demonstrated that damage to the NABT had an impact on clinical 
progression in PPMS, and could be detected by measuring MTR and atrophy. 
However, while the MTR histogram and brain segmentation methods described 
suggest that grey matter damage is particularly relevant in this group, these 
techniques can not locate the damage more specifically. 
 
In this study, we used a voxel-based methodology, in which all images were 
spatially normalized into standard space. This allows a voxel-by-voxel statistical 
comparison between patients and a control group, so that all parts of the grey 
matter are investigated. The technique avoids the bias introduced when using an a 
priori hypothesis, for example in ROI analysis (see sections 2.8.4.1 and 2.8.4.3). 
The technique was previously applied to localize grey matter atrophy in a subgroup 
of our cohort, and thalamic atrophy was identified (Sepulcre 2006). In the present 
study we implemented methodological improvements to maximize the sensitivity of 
the technique, and increased the study population, in order to test for atrophy not 
only in the deep grey matter but also in the cortex.  
 
We aimed to localize both grey matter MTR changes and atrophy, to establish the 
relationship between the processes reflected by each technique. In addition, we 
assessed the direct clinical impact of the MTR changes by correlating them with 
clinical scores for the functional systems relevant to the damaged areas, while 
taking into account volume loss within the regions of reduced MTR. Understanding progression in PPMS: Chapter 4     115   
4.2 Methods 
 
4.2.1 Subjects 
 
As described in section 3.1.2.1, fifty patients with definite or probable PPMS 
(Thompson 2000), within five years of symptom onset, were invited for radiological 
assessment and scored on the EDSS and MSFC. As described previously, one 
patient did not complete the baseline protocol, and another developed 
claustrophobia. One patient withdrew after baseline, but was retained in the 
present study. Two patients were excluded from this study on the basis of their 
images (see section 4.2.2). Thus a total of 46 patients entered the present study 
(19 female, 27 male; mean age 43.5 years, range 19 to 65 years; see Table 4.A  
for patient characteristics), and twenty-three healthy controls were also scanned 
(12 female, 11 male; mean age 35.1 years, range 23-56 years). The difference in 
age between patients and controls was adjusted for at each stage of the analysis, 
as described below.  
 
 
Table 4.A Characteristics of patients and controls 
 
  Patients (n=46) 
 
Controls (n=23) 
Age in years (range)  43.5 (19-65)  35.1 (23 -56) 
Gender female/male  19/27  12/11 
EDSS median (range)  4.5 (1.5-7)  - 
Disease duration in years (range)  3.3  (2-5)  - 
T2 lesion load in ml (SD)  13.39 (19.61)  - 
 
SD=Standard deviation, EDSS=Expanded Disability Status Scale, n=number Understanding progression in PPMS: Chapter 4     116   
 
4.2.2 Image acquisition and post-processing  
 
A 1.5 Tesla GE Signa scanner (General Electric, Milwaukee, Wisconsin, USA) was 
used to acquire the images. MTI and T1-weighted FSPGR sequences were 
acquired as described in section 3.1.2.2. The images were transferred to a Sun 
workstation (Sun Microsystems, Mountain View, CA) for post-processing. MTR 
maps were calculated from the PD images as described in section 3.1.2.3. The 
following processing, except the creation of the lesion mask, was done in SPM2 
(Wellcome Department of Cognitive Neurology, London, UK). 
 
4.2.2.1 Lesion mask creation 
Lesions were contoured on the unsaturated PD images from the MT sequence as 
described in section 3.1.2.3, and binary lesion masks created for each patient. The 
lesion mask was smoothed with an 8mm full width at half maximum (FWHM) 
isotropic Gaussian kernel. Voxels at the lesion boundary with intensity less than 
one were set to zero, so that any voxel containing lesional and peri-lesional tissue 
would be included in the mask and therefore excluded from the analysis (see 
below). 
 
4.2.2.2 Co-registration of MTR and T1-weighted images 
PD-weighted scans from the MT sequence were co-registered to the 
corresponding T1-weighted volume, using normalized mutual information as the 
cost function (Studholme 1997). The same transformation was then applied to the 
MTR map and lesion mask, so that all images were in the space of the T1-
weighted volume. 
 
4.2.2.3 Segmentation of the T1-weighted images in native space 
Segmentation of the T1-weighted volume image was performed in native space in 
SPM2, as described in Chapter 3 section 3.2.2.3. Lesion masks were applied to 
patients’ scans to remove any lesional tissue erroneously classified as grey or 
white matter.  
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4.2.2.4 Normalization of segmented images  
The use of lesion masks excluded lesions from the normalization process by 
assigning them a zero weighting. The grey matter T1 segmented images were 
normalized into MNI (Montreal Neurological Institute) stereotactic space using a 12 
parameter affine transformation, optimized using 16 non-linear warps (Ashburner 
1997). Optimized transformation parameters were noted and used again later.  
 
4.2.2.5 Normalization of the original T1-weighted images, lesion masks and MTR 
maps 
The optimum parameters obtained from normalizing the NAGM T1-weighted 
images as described above were then applied to the original T1-weighted images. 
This optimized methodology is used because normalization is ideally performed on 
segmented images, so that structural differences affecting normalization do not 
influence segmentation; however, segmentation is optimally performed on 
normalized images corresponding to the a priori T1 template (Good 2001). The 
same transformation parameters were applied to MTR maps and lesion masks. 
 
4.2.2.6 Segmentation in stereotactic space 
Normalized T1-weighted images were then segmented in stereotactic space to 
produce grey matter, white matter, and CSF segments, as explained above. 
Normalized lesion masks were applied to the grey matter segments to ensure no 
lesions were included erroneously. 
 
4.2.2.7 Production and application of grey matter mask 
A conservative threshold of 0.75 (Smith 2006) was applied to the grey matter 
segment from the FSPGR image produced in Step 6, as described in section 
3.2.2.3. Thus only those voxels with a 75% or more likelihood of being situated in 
the grey matter were used to compute a binary grey matter mask in SPM2. This 
mask was then applied to the MTR map, to produce a conservative NAGM MTR 
map. The voxel size was 1mm
3. 
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4.2.2.8 Smoothing 
MTR maps and T1-weighted images were smoothed with a 12mm FWHM 
Gaussian kernel, which rendered the data more statistically normal for analysis by 
SPM2, and corrected for errors during normalization.   
 
The post-processing output on each patient was checked at each stage, and two 
patients were excluded from the study. The first had extensive and severe global 
atrophy far in excess of the rest of the group, making normalization to the T1 
template problematic. The second had an extremely high lesion load causing a 
segmentation failure in which white matter was incorrectly included in the grey 
matter segment, as described in section 3.1.2.3. 
 
4.2.3 Location of Regions with abnormal MTR and grey matter volume 
 
Comparisons of grey matter MTR and volume between patients and controls were 
performed in SPM2 using analysis of covariance adjusted for age, and using a 
family-wise error correction at p<0.01 for multiple comparisons at voxel level 
across the whole brain. This produced maps depicting regions where MTR and 
grey matter volumes were significantly lower in patients. Regions comprising 
clusters of less than one hundred voxels were excluded from the analysis, which is 
a relatively conservative threshold (Ceccarelli 2008, Henry 2008). We calculated a 
mean MTR for each region where MTR was significantly reduced.  
 
To investigate the relationship between abnormal regions in the deep grey matter 
and cortex, Pearson’s correlation were carried out (in SPSS 11.0 [Statistical 
package for the Social Sciences, Chicago, IL, USA]) between the mean MTR in the 
thalamic regions and regions in the motor, somato-sensory, temporal and occipital 
cortex.  
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4.2.4 Correlations between MTR in abnormal regions and clinical measures 
 
Z-scores (z) for MSFC subtests were calculated using our own sample as 
reference, and used to obtain the MSFC (Cutter 1999). Correlations between 
clinical scores and the mean MTR in selected regions with reduced MTR (chosen a 
priori) were carried out in SPSS. From among the regions where patients showed 
reduced MTR compared to controls, we selected those within the motor network 
and within areas reported as relevant to PASAT performance. The motor regions 
were the pre- and post-central gyri, from which the cortico-spinal tract originates 
(Toyoshima 1982). Mean MTR in these regions was correlated with disability 
(EDSS) as well as mobility and upper limb function test scores (zTWT and zNHPT 
respectively). Regions selected as relevant to PASAT performance were: superior 
and middle frontal cortex, inferior parietal cortices and precuneus, superior 
temporal, inferior and medial occipital cortices. These regions were reported to 
activate during PASAT testing in functional MRI (fMRI) experiments in controls and 
patients with relapsing and remitting MS (RRMS) (Forn 2006, Audoin 2005, 
Mainero 2004, Audoin 2003). Mean MTR for each of these regions was correlated 
with the zPASAT score.  
 
We wanted to identify whether MTR was associated with any of the clinical scores 
collected, so a general linear model was performed separately for each clinical 
measure using SPM2. Clinical score was the dependent variable and MTR within 
the selected region was the covariate. As the zTWT scores were not normally 
distributed, the inverse zTWT score was used as this rendered the data more 
normal (izTWT). Models were adjusted for age and gender where they significantly 
affected the model. R values were obtained using partial correlations adjusted for 
the same covariates as the general linear model. Since MTR can be affected by 
partial volume effects in voxels containing CSF or white matter in addition to grey 
matter, we always adjusted models for the grey matter volume within precisely the 
same voxels in which the MTR was reduced. To calculate this value we used 
MRIcro software (http://www.sph.sc.edu/comd/rorden/mricro.html). Abnormal MTR 
regions were delineated as regions of interest (ROIs), and a separate ROI mask 
created for each region. The masks were then applied one by one to the Understanding progression in PPMS: Chapter 4     120   
segmented grey matter maps, to extract the grey matter volume for each individual 
in each region of abnormal MTR (normalized to the voxel size).  
 
4.2.5 Post hoc analysis on the region in the left pre-central gyrus 
 
Having co-registered scans from different sequences with different resolutions and 
then normalized them into standard space, we wanted to be certain that the 
anatomical location of our abnormal regions was correct, and that the MTR 
changes identified reflected genuine grey matter abnormalities. We used a post 
hoc analysis similar to that described by Sommer (Sommer 2002). We chose to 
perform this on the region identified in the left pre-central gyrus, because the MTR 
reduction in this region in patients was highly significant, and correlated with 
clinical measures of disability, but the region was sufficiently small to make 
accurate localization relevant. First, we extracted the transformation parameters 
used to put the T1-weighted image into standard space using SPM2, and inverted 
them using the SPM Deformation Toolbox. We applied the inverted transformation 
parameters of each individual patient’s T1-weighted image in turn to the ROI mask 
for the abnormal region in the left pre-central gyrus (created above). This produced 
an ROI mask of the abnormal region in the left pre-central gyrus in the space of the 
native T1-weighted image. We then reversed the rigid body transformation 
originally used to register the MTR image onto the T1-weighted image, producing 
an image of the ROI mask in the space of the original MT image. This allowed us 
to check the location of the region on each original scan in native space, and to 
obtain the mean MTR for this region from the original images. Finally, we 
compared the mean MTR in this region between patients and controls (in SPSS) 
using a general linear model adjusted for age, where MTR was the dependent 
variable and patient or control status and age were covariates. 
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4.3 Results 
 
4.3.1 Location of regions of reduced MTR and atrophy  
 
4.3.1.1 Cortical grey matter 
In patients, all cortical regions with significantly reduced grey matter volume 
overlapped with regions with significantly reduced MTR (see Figure 4a and Table 
4.B). The largest and most significant (p<0.001) regions of cortical reduction in 
MTR and grey matter volume were in the right pre-central gyrus (Brodmann area 
[BA] 4), but regions were also present in the right middle frontal gyrus (BA 44), left 
post-central gyrus (BA3), and left insula. 
 
Reduced MTR without significant atrophy was seen in the left superior frontal gyrus 
(BA 9/46), left pre-central gyrus (BA 4), right inferior parietal cortex and precuneus 
(BA7), right insula, bilateral superior temporal gyrus (BA 42 and 22), and right 
medial and bilateral inferior occipital cortex (BA 17 and 18; see Table 4.B). 
 
4.3.1.2 Deep grey matter 
In both thalami the region of reduced MTR extended anteriorly, laterally and infero-
laterally, encompassing the anterior, ventral anterior, ventral lateral, ventral 
posterior and lateral geniculate nuclei and pulvinar (see Table 4.B). The right 
thalamus contained the region with the most significantly reduced MTR in the 
whole brain (p<0.001).  
 
Moderate correlations were present between the mean MTR in the thalamic 
regions and in all the regions identified in connected areas of cortex: motor cortex, 
somato-sensory cortex, temporal and occipital cortex (p< 0.001, r value between 
0.60 and 0.80 in all cases). Understanding progression in PPMS: Chapter 4     122   
 
Figure 4a: Regions of significantly reduced MTR and grey matter volume in 
patients compared to controls 
 
 
 
       
             z = 48                            y = -14                                  x = 49.8 
 
The top row shows regions of MTR reduction, in red. The middle row shows regions of 
atrophy, in yellow. The bottom row shows regions of MTR and atrophy superimposed to 
demonstrate the degree of overlap, shown in orange. 
 
x, y and z are the Montreal Neurological Institute co-ordinates, in mm. MTR=magnetization 
transfer ratio Understanding progression in PPMS: Chapter 4     123   
 
 
Table 4.B Regions with significantly reduced MTR and grey matter volume in 
patients compared to controls 
 
* p value after family wise error correction of p<0.01 at voxel level 
BA=Brodmann area, MTR=magnetization transfer ratio, MNI= Montreal Neurological 
Institute, R=Right, L=Left 
 
 
 
 
 
Gyrus/portion 
 
 
 
 
 
BA 
MTR  ATROPHY 
 
MNI co-
ordinates of 
maxima 
 
Number 
of 
 voxels 
 
p 
value* 
 
MNI co-
ordinates 
of maxima 
 
Number 
of 
 voxels 
  
p 
value* 
 
Frontal  
Superior   
 
L  9/46  -23   49   25  718  0.001  -  -  - 
Middle 
 
R  44   43   10   37 
 
408 
 
<0.001 
 
44   10   37  19  0.004 
Pre-central 
 
R 
 
4  40   -23  50  3916  <0.001  41   -22   52  2520  <0.001 
R 
 
4  -  -  -  56   -9   40  139  <0.001 
L 
 
4 
 
-45   -13   43 
 
1850 
 
<0.001 
 
-  -  - 
 
Parietal 
Post-
central  
 
L  3  -49   -12   23  1131  <0.001  -47   -19  57  234  <0.001 
Inferior  R 
 
7  34   -62   46  194  0.003  -  -  - 
Precuneus  R 
 
7  10   -56   43  120  0.002  -  -  - 
 
Temporal 
Superior  
 
R  22  
 
63   -29    -9 
 
430 
 
0.004 
 
-  -  - 
L  42 
 
-51   -42    17 
 
351 
 
0.001 
 
-  -  - 
 
Occipital 
Medial  R  17 
 
15   -67   14 
 
316 
 
0.002 
 
-  -  - 
R  17 
 
10   -82   -1 
 
175 
 
0.002 
 
-  -  - 
Inferior 
 
 
R 
 
18  28   -90   -9  244  0.002  -  -  - 
L  18  -27   -92   -10  270  <0.001 
 
-  -  - 
L 
 
18  -10   -79   -2  532  <0.001  -  -  - 
 
Insula 
  R 
 
13  36   3   4  1036  0.002  -  -  - 
L 
 
13  -37   5   1  1190  <0.001  -36   5   0  558  <0.001 
 
Thalami 
Anterior, 
Lateral, 
Infero-
lateral 
R  -  20   -28   2  1152  <0.001  21   -26   7  1092  <0.001 
Anterior, 
Lateral, 
Infero- 
lateral 
L  -  -8   -12   5  778  <0.001  -10   -10   9  794  <0.001 Understanding progression in PPMS: Chapter 4     124   
 
4.3.2 Clinical correlations with MTR in abnormal regions after adjusting for atrophy 
 
4.3.2.1 Motor function 
Clinical scores correlated with mean MTR in the regions identified as different to 
controls within the pre- and post-central gyri (see Table 4.C). Patients with greater 
disability measured by EDSS, MSFC, NHPT and TWT scores had a lower MTR in 
these regions.  
 
4.3.2.2 Cognition 
zPASAT correlated with mean MTR in the right inferior parietal cortex (BA 7; 
p=0.043, r=0.30) and right inferior occipital gyrus (BA 18; p=0.04, r=0.30). There 
was a trend to correlation between the zPASAT and mean MTR in the abnormal 
region identified in the left superior frontal gyrus (BA 9; p=0.06, r=0.28).In these 
regions, lower zPASAT scores correlated with lower MTR values. In the remaining 
regions identified, there were no correlations between zPASAT score and MTR.  
 
4.3.2.3 Post hoc Analysis 
When the abnormal region identified in the left motor cortex was translated back 
into native space and applied to the original MTR map, the position of the region 
was shown to be consistent in all subjects (see Figure 4b for examples). The mean 
MTR obtained in this region from the original MTR map was significantly lower in 
patients than in controls (p=0.001). 
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Table 4.C Correlation between mean MTR in abnormal regions found within 
the motor network and clinical measures of disability 
 
  EDSS  zNHPT  
 
izTWT  MSFC 
p  r  
 
p  r    p  r    p  r   
Frontal 
Pre-
central 
(BA 4) 
R  0.013  -0.37   <0.001  0.49  0.013  0.37  <0.001  0.53 
L  0.004  -0.43 
 
<0.001  0.55  0.001  0.48  0.001  0.49 
 
Parietal 
Post-
central 
(BA 3) 
L   0.001  -0.50 
 
<0.001  0.56  <0.001  0.53  0.001  0.50 
 
EDSS= Expanded disability status scale, zNHPT= z-score for the nine hole peg test, 
izTWT= inverse of z-score for the timed walk test, MSFC= Multiple sclerosis functional 
composite, BA= Brodmann area 
 
 
 
Figure 4b: The abnormal region in the left pre-central gyrus translated back 
into native space and applied to the original PD-weighted MTR images 
 
 
 
                       PATIENT                                                    CONTROL 
 
         
 
The number on the left of the image is the slice number Understanding progression in PPMS: Chapter 4     126   
4.4 Discussion 
 
It has been widely accepted that the NABT changes contributing to clinical 
progression are likely to be diffuse (Filippi 2003). In this study we report for the first 
time that focal regions of damage occur in the cortex and deep grey matter in early 
PPMS, as demonstrated by localized regions of MTR reduction and atrophy, and 
that they contributes to disability.  
 
4.4.1 Regions of reduced MTR and atrophy  
 
4.4.1.1 Cortical Regions 
The largest and most significant cortical regions of MTR and volume reduction 
were in the pre-central gyrus (BA 4), indicating severe damage to the primary 
motor cortex early in the disease course of PPMS. Reduced MTR and grey matter 
atrophy were also found in: the post-central gyrus (left somato-sensory cortex, BA 
3 in particular); left insula, a highly connected brain area integrating information 
from a number of functional systems; and the right middle frontal gyrus, which may 
be involved in the directed forgetting of unwanted memories (Aron 2004). It should 
be noted that although there was no region with a local maximum in the right post-
central gyrus, the pre-central gyrus cluster was very large and extended into the 
post-central gyrus. MTR reduction alone involved a number of additional areas, 
including the right somato-sensory association cortex; right insula, bilateral 
superior temporal gyri, which are involved in lexical-semantic processing (Koeda 
2006); and the bilateral visual cortex.  
 
4.4.1.2 Deep Grey Matter Regions 
Thalamic damage has been noted from the earliest stages of MS (Mesaros 2008, 
Derache 2006, Geurts 2006, Audoin 2004), and this was the area that differed 
most significantly from controls in our cohort. The anterior thalamic centres are 
connected to the motor and pre-motor cortex, and the infero-lateral areas to the 
somato-sensory, temporal and occipital cortex (Behrens 2003). Thus the areas of 
thalamus affected correspond with areas where we found cortical damage, and Understanding progression in PPMS: Chapter 4     127   
indeed there was a moderate correlation between the MTR in the thalamic regions 
identified and those identified in connected areas of cortex. 
 
It remains uncertain whether the cortical and deep grey matter damage is a 
primary pathological process, whether it is due to lesions within the grey matter, or 
whether it is secondary to white matter lesions causing retrograde or Wallerian 
neuro-axonal degeneration (Brownell 1962). A study in RRMS found a significant 
relationship between focal thinning in the cortex and white matter lesion load 
(Charil 2007) in a large cohort, and more recently T2 lesion volume has been 
shown to correlate strongly with thalamic atrophy in PPMS (Ceccarelli 2008). 
Recent work suggests that lesions in PPMS may have a predilection for the 
cortico-spinal tract (Di Perri 2008), but examination of larger cohorts will be 
necessary to confirm this. 
 
4.4.1.3 Relationship between MTR reduction and Atrophy 
As expected, MTR reduction was always present in regions with significant 
atrophy. The pathological substrate of grey matter MTR reduction remains unclear. 
However, post mortem studies in NAWM suggest that while MTR reduction reflects 
axonal loss, and thus essentially areas of tissue atrophy, this is probably 
secondary to its sensitivity to demyelination (Schmierer 2004). This may explain 
the incomplete overlap in the cortex and the thalamus, where regions of MTR 
reduction tend to extend beyond regions of atrophy. MTR reduction in these areas 
may, in addition to axonal loss, also reflect a qualitative change in the atrophied 
tissues. This is likely to represent demyelination of remaining neuro-axonal tissue 
(Schmierer 2004), which is a common finding in pathological studies of the grey 
matter in MS (Geurts 2005), but other reversible processes such as oedema and 
inflammation may also contribute.  
 
This raises the possibility that regions showing reduced MTR in the absence of 
atrophy are demonstrating reversible change, where irreversible neuro-axonal loss 
has not yet occurred. If this were the case, these regions would be vulnerable to 
atrophy in the future. Indeed, regions showing MTR reduction alone in our study in 
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other studies (Prinster 2006, Chen 2004, Sailer 2003). Comparisons between 
heterogeneous studies must, however, be made with caution, and longitudinal 
studies are necessary to investigate this hypothesis. 
 
4.4.1.4 Methodological considerations 
There is debate surrounding the use of voxel-based analysis (Davatzikos 2004, 
Bookstein 2001), and in particular its application to quantitative data (Smith 2006, 
Jones 2005). In all voxel-based analyses, normalization of images into standard 
space necessitates a degree of interpolation, and images are then smoothed to 
render the data normal for statistical analysis. In addition, we co-registered MT and 
volume sequences which had different slice thicknesses. These aspects may have 
influenced our results by compromising accurate localization of abnormal regions, 
and by increasing the number of partial volume voxels, which contain other tissues 
along with grey matter, in the image. 
 
In this study, we minimized registration biases by using an optimized technique, so 
that significant regions identified are clearly attributable to grey matter differences. 
In addition, we applied a very conservative threshold to our grey matter masks, so 
that only voxels with greater than 75% likelihood were included. This threshold 
minimized the effect of partial volume voxels containing CSF or white matter in 
addition to grey matter (which may alter the MTR measurement; see section 
2.8.4.3) on the analysis, while still allowing the detection of atrophy. Although the 
combination of a conservative threshold (75%) and a relatively large smoothing 
kernel (12mm) may reduce the overall accuracy of the localization, using the 
threshold increases the certainty that the abnormal regions are situated in the grey 
matter. In addition, in order to confirm the anatomical position of the abnormal 
regions on the original images in native space, and to confirm that our findings 
were genuine, we performed a post hoc analysis on one of the abnormal regions. 
When the region was translated back into native space and applied to the original 
image, our results were confirmed; both qualitatively, by assessing the anatomical 
position of the region, and quantitatively, by confirming post hoc the significant 
difference in mean MTR values between patients and controls. 
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We used PD-weighted rather than T1-weighted MT sequences because T1 effects 
are known to affect the MTR (Finelli 1998, Hajnal 1992). However, poor grey-to-
white matter contrast in PD-weighted sequences made it necessary to include the 
additional step of co-registering the MT sequence to the volume images to perform 
the segmentation accurately. For these images, this method is likely to produce 
more accurate results than direct normalization of MT images onto a template. 
Furthermore, in a recent study comparing automated segmentation methods, SPM 
was shown to have an accuracy advantage over FSL and Freesurfer, although 
SPM5 was tested rather than SPM2 as used in our study (Klauschen 2009). The 
intra-subject co-registration was optimized in this study by the use of a voxel-
intensity registration measure known to work well for images of different contrasts, 
namely normalized mutual information (Studholme 1997). 
 
4.4.2 Clinical correlations 
 
4.4.2.1 Motor function 
Correlations were present between clinical tests of disability and regions of MTR 
reduction within the motor network, suggesting that the local MTR reduction 
identified is contributing to the clinical status of the patient. However, the moderate 
nature of our associations suggests that damage in other areas, such as the white 
matter and spinal cord, may also be contributing to functional impairment. 
 
PPMS tends to present with locomotor disability (Sailer 2003), and this was the 
most common presentation in our cohort. There is some indication that damage to 
the motor cortex occurs later in other types of MS (Sailer 2003). Localized damage 
in the somato-sensory, but not the motor, cortex, is apparently greater in SP 
compared to RRMS, and greater in SP than in PPMS (Ceccarelli 2008). This 
suggests that differences in symptom prevalence between disease subtypes may, 
in part, reflect differential patterns of cortical predilection.  
 
4.4.2.2 Cognition 
MTR in regions in the right inferior parietal cortex and right inferior occipital gyrus 
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reduced ability to perform the task. There was a trend to correlation with MTR in 
the left superior frontal gyrus (left lateral prefrontal cortex BA9 and BA 46), which 
has been identified in a number of functional MRI studies as a key functional area 
for the PASAT test (Forn 2006, Audoin 2005, Mainero 2004). However, damage to 
other areas known to be active during PASAT testing did not correspond with lower 
PASAT scores (middle frontal gyrus [BA 44] and superior temporal gyrus [BA 42 
and 22], medial occipital cortex [BA 17]). Notably, these areas were identified in 
patients with RRMS (Forn 2006, Mainero 2004), and specific combined MT and 
fMRI studies would be necessary to confirm which areas are functionally relevant 
during PASAT testing in our own cohort. Furthermore, correlations between MTR 
in these regions and PASAT scores may be weak because damage in other brain 
areas, such as the white matter, makes an important contribution to cognitive 
impairment. The findings of a recent study in RRMS, which identified a relationship 
between localized peri-ventricular atrophy and PASAT performance (Jasperse 
2007), lends some support to this hypothesis. 
 
4.5 Conclusions 
 
This study demonstrates that areas of grey matter damage, reflected by MTR 
reduction and atrophy, can be localized to specific sites of predilection early in the 
course of PPMS. Localized regions of MT change are more widespread than 
localized regions of atrophy, and the two measures may provide complementary 
information. Clinically, localized MT reduction is expressed as disability in the 
systems related to the damaged areas.  Understanding progression in PPMS: Chapter 4     131   
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Enhancing Lesions: 
 The role of inflammation in early PPMS 
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5.1 Introduction 
 
The concept that primary progressive multiple sclerosis (PPMS) may be 
pathologically distinct from other MS subtypes gained momentum in the late 
1980’s, when its characteristic MRI features were first described (Thompson 1990). 
Fewer and smaller lesions, demonstrating relatively little enhancement with 
gadolinium-DTPA (gadolinium-diethylenetriaminepentaacetic acid) were seen in 
PPMS (Thompson 1991). Post-mortem investigations have since confirmed a 
relative paucity of inflammation in PPMS lesions. In comparison to SPMS, fewer 
perivascular cuffs, reduced parenchymal cellularity (Revesz 1994), and a relative 
reduction in T and B cell infiltrates have been described (Magliozzi 2007, 
Lucchinetti 2004). Furthermore, there are relatively few active lesions in PPMS; 
instead established lesions show a tendency to radial expansion (Kutzelnigg , 
Prineas Annals 2001). Radiological studies have demonstrated that this expansion 
is largely responsible for increases in T2 lesion load (Stevenson 2002). 
It was therefore somewhat surprising that, in a subgroup of our cohort with early 
PPMS, 42% had at least one enhancing lesion at baseline after administration of  
triple dose (0.3mmol/kg) gadolinium (Ingle 2005). This is three times the 
percentage of patients demonstrating enhancement in the PROMiSe trial (Wolinsky 
2004), although single dose gadolinium was used in the latter study. This raised 
the possibility of an early enhancing phase in PPMS, a finding which may have 
therapeutic implications. In addition, the patients with enhancement were more 
disabled, with a higher T2 lesion load and reduced partial brain volume, compared 
to those without enhancing lesions. This raises the possibility that enhancement is 
a poor prognostic feature. 
 
In this study we followed patients with early PPMS over five years, to investigate 
whether they continued to show the same level of enhancement. We also 
investigated whether enhancement influenced clinical progression, or correlated 
with changes in MRI markers over this period.  
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5.2 Methods  
 
5.2.1 Subjects 
 
As described in section 3.1.2.1, fifty patients fulfilling the diagnostic criteria for 
definite or probable PPMS (Thompson 2000), within five years of symptom onset, 
were invited to attend for clinical assessment and scanning every six months for 
three years, and again at five years. The clinical assessment involved neurological 
examination and scoring on Kurtzke’s Expanded Disability Status Scale (EDSS) 
(Kurtzke 1983) and multiple sclerosis functional composite (MSFC) (Cutter 1999) 
at each time-point. The scanning protocol is described below. Five patients were 
excluded from the study: two patients declined gadolinium injections, two patients 
were taking regular courses of oral steroids prescribed by their GPs, and one 
patient died during the first year of the study. Thus 45 patients were included in this 
study (28 male, 17 female, mean age 44.2 years, range 19-65 years). Median 
EDSS was 4.5 (range 1.5-7) at the start of the study, with mean disease duration of 
3.4 years (range 2-5 years). The number of patients attending each study time-
point is given in Table 5.A. During the study some patients became too disabled to 
undergo scanning or no longer felt able to attend our centre, and one became 
claustrophobic. In addition, three patients were unable to undergo gadolinium 
injections because the normality of their renal function could not be established 
prior  to the scan. In these cases we obtained EDSS data in person if possible, or 
using a telephone interview (Lechner-Scott 2003). Patients taking short courses of 
disease modifying or anti-inflammatory medications were excluded from the 
analysis at that time-point (see Table 5.A). A total of 38 patients (24 male, 14 
female, mean age 44.4 years, range 19-63) completed the study.  
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Table 5A Patients attending at each time-point 
Personal Commitments= patients were unable to arrange an appointment during the six 
month period due to personal commitments, eg work, holiday and family commitments. 
Upgrade= scanner undergoing upgrade during this time-point. Drugs= patients taking 
drugs which affect gadolinium enhancing lesions (the patient excluded at 36 months had 
intra-venous steroids within 6 weeks of the scan, the patient excluded at 60 months was 
being treated with mitoxantrone for rapid clinical deterioration with superimposed relapses 
unresponsive to steroids). Patients had a clinical assessment only if they were unable to 
attend the centre, or if their renal function was not proven to be normal.  
 
Time-point  
(months) 
0  6  12  18  24  30  36  60 
Total patients assessed:  45  38  34  33  34  29  40  38 
Patients given gadolinium   45  37  32  31  28  25  30  19 
Patients with clinical 
assessment only 
0  1  2  2  6  4  10  19 
Patients who did not 
attend: 
0  7  11  12  11  16  5  7 
Withdrew from study  0  1  1  1  1  2  2  2 
Personal commitments  0  5  7  7  7  8  0  0 
Non-MS related illness  0  1  2  3  3  5  1  1 
Upgrade  0  0  1  1  0  0  0  0 
Death  0  0  0  0  0  0  1  1 
Could not be contacted  0  0  0  0  0  1  0  2 
Drugs  0  0  0  0  0  0  1  1 Understanding progression in PPMS: Chapter 5     138 
5.2.2 MRI Acquisition 
All scans were performed on a 1.5 Tesla GE Signa scanner (General Electric Co, 
Milwaukee, Wisconsin, USA). The mean and median times between scans for 
each six-month time-point were 26.7 and 26.5 weeks respectively (range 25.3-29.0 
weeks), and between the three and five year time point were 101.2 and 100 weeks 
(range 46.7 to 166.3 weeks). The scanner was upgraded during the study, and the 
gradient amplifiers, but not the gradient coils, were changed. Maximum gradient 
strength increased from 22mTm
-1 to 33mTm
-1. The scanner software was 
upgraded from SIGNA version 5x to version11x. At each time-point imaging of the 
brain and spinal cord was carried out as follows: 
1. Axial T1-weighted spin echo sequences of the brain were acquired before and 
after injection of triple dose gadolinium-DTPA (0.3mmol/kg). The acquisition 
comprised 28 contiguous slices of 5mm thickness, with a repetition time (TR) of 
540ms, and an echo time (TE) of 20m/s, field of view (FOV) 240 x 240, number of 
excitations (NEX)=1. Sagittal T1-weighted spin echo images of the spine were  
also acquired before and after gadolinium injection, with a slice thickness of 3mm 
TE  of 18ms, TR of 500ms, FOV 48x24 , NEX=3. Parameters were not changed 
after the upgrade. 
 
2. T2-weighted images were acquired as described in section 3.2.2.2, as part of 
the MTI sequence (Barker 1996). Parameters were not changed after the upgrade. 
 
3. 3D inversion-prepared fast spoiled gradient recall (3D FSPGR) sequence of the 
brain was acquired as described in section 3.2.2.2. After the upgrade the TR was 
reduced to 10.9 ms.  
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5.2.3 MRI post-processing 
 
Gadolinium enhancing lesions were identified, marked and counted on hard copies 
of the T1 -weighted images, by an experienced neuro-radiologist blinded to the 
clinical details of the patients.  
Images were displayed on a Sun workstation (Sun Microsystems, Mountain View, 
CA) using DispImage software (Plummer 1992). Calculation of the T2-weighted 
lesion load and segmentation of the FSPGR images was carried out as described 
in section 3.2.2.3, for images from baseline to three years. 
 
5.2.4 Statistical Analysis  
Analysis was carried out using Stata (http://www.stata.com). 
Statistical significance is reported at the 5% level.  
5.2.4.1 Clinical data 
We converted the change in EDSS scores into step changes as described in 
section 3.1.2.4.1. Z-scores (z) were derived for the MSFC subtests using our own 
baseline sample as reference, and used to calculate the MSFC.  Patients who 
were too disabled to complete the TWT and NHPT were initially given a score for 
the maximum time allowed (see section 3.1.2.4.1) but the statistical models were 
invalidated because the data was no longer normally distributed. They were 
therefore excluded from the analysis, and full details of this subgroup are given in 
Table 5.B.  
 
5.2.4.2 Gadolinium measures 
As in the PROMiSe trial (Wolinsky 2007), we examined the number of gadolinium 
enhancing lesions rather than the gadolinium lesion load, a measure easily 
applicable in a clinical setting. In PPMS lesions tend to be smaller (Thompson 
1991) and the lesion number is likely to reflect lesion load. We formulated the 
following measures, which were entered one by one into the models described 
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status measure [ie. enhancing/non-enhancing], categories of enhancement [0, 1-3, 
or > 3 enhancing lesions]); Early changes (change in number of enhancing lesions 
from baseline to six months, change in number of enhancing lesions from baseline 
to one year); Overall changes at three and five years (total number of enhancing 
lesions, overall binary enhancement status [enhancing/non-enhancing], categories 
of enhancement [<3, 3-9 or >9 enhancing lesions], percentage of time-points with 
enhancing lesions for each subject). 
 
5.2.4.3 Changes in MRI parameters over five years 
To model the change in the percentage of patients with enhancing lesions at each 
study time-point, we used a mixed effect logistic model with the binary 
enhancement variable as the response variable and months from study entry as 
predictor. This allows estimation of the reduction in odds of enhancement per 
month. We included a quadratic term in time to assess the linearity of the data. To 
ensure that the upgrade had not altered the detection of enhancing lesions we 
compared the number of enhancing lesions in pre- and post- upgrade groups at 
each time-point using unpaired 2-tailed t-tests. The calculation of volume and T2 
lesion changes over three years, using piecewise mixed effect linear regression 
models adjusting for the upgrade, are described in detail in section 3.2.2.4.2. 
 
5.2.4.4 Predicting clinical changes over three and five years 
We compared clinical outcome between patients with spinal cord and other 
presentations using Mann-Whitney U tests (for EDSS changes) and t-tests (for the 
MSFC and subtests). First we examined clinical changes over three years, and 
then over five years. To identify predictors of EDSS change over three and five 
years, ordinal logistic regression was carried out with EDSS change as the 
response variable. Each enhancing lesion parameter was tested as a covariate in 
turn, and the model was adjusted for age and T2 lesion volume at baseline. For 
changes in MSFC and its subtests, a multiple linear regression was carried out with 
the change in the MSFC and each subtest in turn as the dependent variable, using 
the same covariates as for the EDSS. 
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5.2.4.5 Correlates of MRI change over three years 
Using multiple linear regression, changes in grey and NAWM volume were 
modeled in turn as the response variable. The enhancing lesion parameters were 
introduced in turn, with age, upgrade, T2 lesion load and interaction terms with 
time as covariates, in order to investigate their effect on the rate of volume change.  
As described in section 3.2.2.4, this model adjusts for any gradient discontinuity 
due to the upgrade. The model was repeated with T2 lesion load as the response 
variable rather than a covariate.  
 
The analyses were run using data on enhancing lesions in the brain only, then 
rerun using data on both the brain and spinal cord.  
 
5.3 Results 
 
5.3.1 Clinical progression 
 
Clinical progression was evident over three and five years on the EDSS, TWT and 
NHPT (see Table 5.2). The PASAT test showed significant improvement, probably 
due to practice effects, which affected the MSFC (section 3.1.4.1). For this reason 
the PASAT and MSFC data were considered flawed. However, we present results 
on the NHPT and TWT subtests. There was no difference in progression between 
the 35 patients presenting with a spinal cord syndrome, and the 10 presenting with 
deficits in other systems. 
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Table 5.B Clinical tests at baseline, three and five years, with separate data 
on the subgroup completing all tests and study time-points 
 
Clinical test  Baseline  3 years  p*  5years  p** 
Median 
EDSS 
(range) 
All   4.5 (1.5-7)  
n=45 
6 (1.5-9)  
n=41 
<0.001  6.5 (2-9)  
n=38 
<0.001 
Pts with 5 year 
EDSS data 
4.25 (1.5-7) 
n=38 
6 (1.5-9) 
n=38 
<0.001  6.5 (2-9) 
n=38 
<0.001 
Mean 
MSFC 
(SD) 
All  0.02 (0.7) 
n=42 
0.14 (0.8) 
n=30 
0.52  0.001 (1.2) 
n=18 
0.11 
Pts with 5 year 
data able to 
complete all 
MSFC subtests 
0.51 (0.4) 
n=14 
0.60 (0.3) 
n=14 
0.34  0.56(0.4) 
n=14 
0.55 
Mean TWT 
in 
seconds 
(SD) 
All   20.2 (37.8) 
n=44 
35.8 (61.1) 
n=34 
0.02  57.6(77.3) 
n=22 
0.06 
Pts with 5 year 
data able to 
complete TWT 
7.0 (2.1) 
n=16 
8.6(4.7) 
n=16 
0.05  11.7(11.1) 
n=16 
0.28 
Mean 
NHPT in 
seconds 
(SD) 
All  38.0 (33.4) 
n=45 
53.9 (63.5) 
n=34 
0.01  50.1(64.6) 
n=21 
0.01 
Pts with 5 year 
data able to 
complete NHPT 
25.9 (5.4) 
n=20 
33.7 (30.9) 
n=19 
0.28  37.6(30.6) 
n=20 
0.01 
Mean 
PASAT 
score  
(SD) 
All   41.6 (13.2) 
 n=43 
 46.8 (14.2) 
n=32 
0.06  47.2(16.6) 
n=21 
0.90 
Pts with 5 year 
PASAT data 
43.1 (12.3) 
n=21 
49.4 (12.1) 
n=20 
0.002  47.2(16.6) 
n=21 
0.90 
 
Pts with 5 year data= the subgroup of patients who attended at five years. Pts with 5 year 
data able to complete test= the subgroup of patients who attended at five years and were 
not too disabled to complete the test. EDSS= expanded disability status scale, obtained in 
person or by telephone, NHPT= Nine Hole Peg Test, TWT= Timed Walk Test, PASAT= 
Paced Auditory Serial Addition Test (maximum score=60). SD= standard deviation. p*= p 
value from Mann-Whitney U (EDSS) and t-tests comparing baseline and three year 
scores. p**= p value from Mann-Whitney U (EDSS) and t-tests comparing three year and 
five year scores  Understanding progression in PPMS: Chapter 5     143 
 
5.3.2 The proportion of patients with enhancing lesions decreased over five years 
 
In the group as a whole over five years, the percentage of patients with enhancing 
lesions in the brain and spinal cord declined significantly over five years (p=0.03). 
The significant quadratic term in time (p=0.046) suggests that most of this decline 
occurred early on; a decreasing decline over time, with eventual leveling off, is 
demonstrated (see Figure 5a). However, in individual patients, both increases and 
decreases were observed in the number of enhancing lesions at each time-point 
(see Table 5C).  
In total, 24 patients demonstrated enhancement in either the brain or cord at one or 
more time-points (see Table 5C for the number of patients with enhancing lesions 
at each time-point), and 21 patients (47%) had no enhancing lesions. Five patients 
showed enhancing lesions in the brain or spinal cord for the first time at six 
months, one at twelve months, two at eighteen months, two at three years, and 
one at five years. Out of a total of 369 enhancing lesions seen over five years, only 
19 were spinal cord lesions, seen in eight different patients. The inclusion of the 
spinal cord lesions in the statistics did not alter the results, and as this additional 
parameter conferred no benefit we present the results using enhancing brain lesion 
parameters only. The number of enhancing lesions detected was not affected by 
the upgrade. 
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Table 5.C The frequency of each number of enhancing lesions identified in 
the brain and spinal cord at each time-point 
 
Number of 
Enhancing 
Lesions 
Time-point 
0  6  12  18  24  30  36  60 
0  30  23  24  25  24  20  24  14 
1  4  7  3  4  0  2  3  3 
2  4  2  0  0  1  0  1  0 
3  1  0  0  0  0  0  0  1 
4  2  1  0  0  2  1  0  0 
5  0  0  1  1  0  0  0  0 
6  2  1  1  0  0  1  0  0 
7  1  0  1  0  0  0  0  0 
8  0  0  0  0  1  0  1  0 
9  0  0  1  0  0  0  0  0 
10  0  1  0  0  0  1  0  0 
11  0  0  0  0  0  0  1  0 
14  1  0  0  0  0  0  0  0 
22  0  1  0  0  0  0  0  1 
26  0  1  0  0  0  0  0  0 
43  0  0  0  1  0  0  0  0 
60  0  0  1  0  0  0  0  0 
Total with 
enhancement 
15  14  8  6  4  5  6  5 
Total imaged  45  37  32  31  28  25  30  19 
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Figure 5a: Percentage of patients with gadolinium enhancing lesions at each 
time-point 
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5.3.3 Enhancing lesions were modestly related to clinical progression 
 
Progression on the EDSS over three years was predicted by the number of 
gadolinium enhancing lesions at baseline (p=0.01, OR 1.32, 95%CI 1.06-1.64), 
and greater increase in the number of enhancing lesions over the first year 
(p=0.047, OR 1.08, 95%CI 1.00-1.16) but this did not survive adjustment for T2 
lesion load. Progression on the EDSS over five years was predicted by the number 
of gadolinium enhancing lesions at baseline (p=0.02, OR 1.28, 95%CI 1.04-1.58), 
but this did not survive adjustment for T2 lesion load. EDSS increase over three 
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and five years correlated inversely with age (p<0.05), and positively with T2 lesion 
load at baseline (p=0.008). 
 
Changes in NHPT score over three and five years, and in TWT score over three 
years, were not predicted by enhancing lesion parameters. Reducing mobility on 
the TWT over five years was predicted by the number of enhancing lesions at 
baseline (p=0.02, coefficient 0.03, 95%CI 0.006 to 0.05, r
2=0.64), and increase in 
enhancing lesion number at 6 months (p=0.02, coefficient 0.004, 95%CI 0.0008 to 
0.008, r
2=0.64) and one year (p=0.046, coefficient 0.02, 95%CI 0.0004 to 0.04, 
r
2=0.70), after correction for age and T2 lesion load. There was an inverse 
correlation with age (p=0.04). 
 
5.3.4 Enhancing lesions were related to T2 lesion load increase but not atrophy 
 
Increase in T2 lesion load over three years correlated with an increase in the 
number of enhancing lesions over one year after adjusting for age (p= 0.048, 
coefficient 2.18 95%CI 0.024 to 4.34, r
2=0.21). Grey and NAWM volume decrease 
was not associated with clinical presentation, age or enhancing lesion parameters.  
 
5.5 Discussion 
 
We report a decline of the initially substantial level of lesion enhancement in 
patients with early PPMS over five years. The level of enhancement towards the 
end of the study (16-21%) is very slightly higher than that found in patients with 
longer disease duration using single dose gadolinium (14%) (Wolinsky 2004). This 
may suggest that there is an early inflammatory phase in a subgroup of patients 
with PPMS. Conversely, almost half of our cohort never showed enhancement, and 
few patients developed enhancement during the study. This may reflect a spectrum 
of activity in PPMS, in which reported cases of ‘pure’ PPMS – clinically progressive 
patients without focal lesions (Zwemmer 2008)- lie at one extreme. Alternatively, 
the non-enhancing patients in our study may have demonstrated enhancement if 
scanned more frequently (Tortorella 1999) or earlier; lesion activity may occur long 
before symptom onset in PPMS (McDonnell 2003). Furthermore, advancing age Understanding progression in PPMS: Chapter 5     147 
may have influenced the reduction in lesion activity in our cohort, as observed in 
RRMS (Tortorella 2005). Indeed, we found more gradual disability accumulation 
and T2 lesion load increase  in older patients.  
 
Active inflammation had only a small impact on future disability in this group. The 
concept of an early inflammatory phase in PPMS raises the possibility of benefit 
from disease modifying treatments in a subgroup, if given early enough in the 
disease course. In the interferon and mitoxantrone studies in PPMS, gadolinium 
was not administered (Montalban 2004, Stuve 2004, Leary 2003). In the glatiramer 
acetate study, treated patients showed a reduction in gadolinium enhancing lesions 
in the first year, but this was not sustained over three years and did not affect 
progression. Mean disease duration in this study was double that in our cohort 
(Wolinsky 2007), but data from other MS subtypes also cautions against over-
anticipating the long term benefits of treatments targeting inflammation. Even in 
RRMS, where enhancement levels correlate more directly with clinical activity 
(Kappos 1999, Barkhof 1992), natural history studies suggest that disability accrual 
is ‘amnesic’ and disregards early relapse history (Confavreux 2006). Furthermore, 
treatments which limit relapse activity and the development of enhancing lesions 
have not affected the progression of disability in SPMS (Giovannoni 2004).  
 
Regarding brain atrophy, suppression of gadolinium enhancing lesions in clinical 
trials has also had minimal impact on this measure (Inglese 2004). In our study, the 
level of lesion enhancement failed to predict atrophy, as it has in other MS 
subtypes (Rashid 2007, Inglese 2005, Zivadinov 2002). However, it may also be 
the case that the relationship between focal lesion activity and eventual brain 
atrophy becomes apparent only after lengthy follow-up.  
 
It should be noted when interpreting this data that triple dose gadolinium was 
administered. RRMS studies suggest that additional lesions detected with triple 
dose gadolinium are less destructive than those already visible with single dose 
(Rovaris 1999), and it may be that the detection of ‘extra’ lesions complicates the 
relationship between enhancement and disability. The relevance of this remains 
unclear in PPMS, because the increased sensitivity using triple dose gadolinium Understanding progression in PPMS: Chapter 5     148 
has not been consistently demonstrated. A study involving ten patients with PPMS 
(Filippi 1995) identified four enhancing lesions in two patients; following a triple 
dose of gadolinium in the same group, 13 enhancing lesions were seen in five 
patients. The patients had a mean disease duration of 6.5 years. In contrast, in 16 
patients with PPMS examined as part of a larger group, no increase in enhancing 
lesion number was found using triple rather than single dose gadolinium (Silver 
1997). Of note, only two enhancing lesions were identified in these patients, who 
had a mean disease duration of nine years. Both studies were small, and it is 
difficult to draw firm conclusions from them. Furthermore, gadolinium enhancement 
may be a more non-specific and less sensitive measure of blood-brain-barrier 
(BBB) breakdown than previously appreciated. A study measuring T1-relaxation 
time in post contrast scans in patients with RR and SPMS, found gadolinium 
leakage in chronic inactive non-enhancing lesions, particularly smaller lesions and 
those which persisted as T1 black holes (Soon 2007). Pathological studies have 
reported ongoing BBB leakage in inactive plaques in PPMS, suggestive of 
defective repair. Interestingly, persistent endothelial abnormalities in grey and 
NAWM have also been demonstrated in PPMS (Leech 2007). Newer MRI 
techniques, such as the ultra-small iron oxide particle (USPIO) enhancement, a 
putative marker of cellular infiltration, may provide complementary information not 
available from gadolinium images (Vellinga 2008, Dousset 2006). These findings 
indicate that BBB dysfunction is more extensive and complicated than previously 
appreciated, and may partly explain the poor correlation between gadolinium 
enhancement and irreversible disability. 
 
The clinical correlations identified in this group were weak. While the TWT in the 
subgroup still walking at five years was predicted by early gadolinium 
enhancement independently of T2 lesion volume, this was not yet evident at three 
years. Progression on the EDSS was predicted by early enhancing lesion 
parameters, but this effect did not survive adjustment for T2 lesion load. 
Nonetheless, this does indicate that enhancing lesion parameters give some 
prediction of EDSS outcome, and enhancing lesion numbers may be a more useful 
clinical tool than overall T2 lesion volume. Furthermore, as enhancing lesions are a Understanding progression in PPMS: Chapter 5     149 
subset of T2 lesions, adjusting the analysis for T2 lesion volume may have 
introduced considerable Type II error.  
 
This study was limited by the number of patients unable to undergo gadolinium 
injection at later time-points, particularly as they were the most disabled patients. 
This may have caused a selection bias by artificially reducing the proportion of 
patients demonstrating enhancement later in the study, and results should be 
interpreted with caution. However, these considerations did not affect the predictive 
part of the analysis, as clinical data was obtained on most patients at five years.  
 
5.6 Conclusions 
Our findings indicate a decline in active lesions over five years, suggesting that 
there is an early inflammatory phase in a subgroup of patients with early PPMS.  
Lesion activity has some influence on clinical progression in the medium term.  Understanding progression in PPMS: Chapter 5     150 
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Conclusions and Future Directions 
Mechanisms and measures of progression 
The mechanisms underlying clinical progression in PPMS are not clearly 
established. Our studies examine the evolution of brain injury in the early phase of 
PPMS in vivo, by measuring changes in brain volume, lesions and magnetization 
transfer ratio (MTR) over time. Our findings suggest that normal appearing white 
matter (NAWM) injury is already established, but remains relatively stable in early 
PPMS. Grey matter injury is evolving more quickly, and appears to be driving 
clinical progression in the medium term. Focal lesions and the level of lesion 
activity in the white matter continue to play a role in determining disability accrual. 
These findings are relevant to inform therapeutic approaches, and suggest that the 
identification of neuro-protective agents is a priority. In addition, they provide data 
for clinical trials in PPMS, which have been limited by the uncertain evolution of the 
condition. Our results suggest that MTR, particularly in the grey matter, is a 
sensitive and responsive measure of brain injury in early PPMS, and that it is 
associated with clinical progression. Therefore, grey matter MTR may be a useful 
measure for selecting and monitoring patients for study in clinical trials in early 
PPMS, possibly in combination with T2 lesion measures. At present our MTR 
findings are applicable only to groups, and can not guide the care of individual 
patients. Studies in larger cohorts will be necessary to confirm our results, and to 
identify clinically applicable thresholds. Future work on our own cohort will aim to 
establish whether grey matter injury, reflected by MTR, continues to drive clinical 
progression over five years; whether irreversible grey matter damage, reflected by 
atrophy, becomes more closely related to concurrent clinical progression, and 
whether the clinical relevance of white matter damage declines over five years.  
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Spinal Cord Studies 
Spinal cord pathology is likely to play an important role in disease progression in 
PPMS. In our study, the level of lesion activity in the spinal cord did not contribute 
significantly to progression, but the number of lesions observed was small. 
Measures of spinal cord atrophy may be a more suitable way to examine the 
impact of spinal cord injury on progression in early PPMS, and will be examined in 
a future study. Technical difficulties have previously hindered MRI studies in the 
spinal cord, but recent improvements in receiver coils and imaging speed have 
allowed the introduction of more sophisticated techniques (Bakshi 2008). Grey 
matter MTR has been used to detect clinically relevant cervical cord damage in 
patients with RRMS, in the absence of atrophy (Agosta 2007). Application of this 
technique in PPMS poses challenges, due to the presence of atrophy and partial 
volume effects, but a combination of MTR and atrophy measures in the grey matter 
could help to elucidate the mechanisms underlying progressive spastic paraparesis 
in early PPMS. High field post mortem MRI studies in the spinal cord have 
indicated that grey matter lesions are more readily detectable in the cord (Gilmore 
2009). As high field MR becomes more widely applicable in vivo, the spinal cord 
may become a prime location for comparing the clinical relevance of grey matter 
lesions with changes in the normal appearing grey matter. 
Understanding grey matter injury 
Having demonstrated the importance of grey matter injury for progression in 
Chapter 3, in Chapter 4 we went on to identify sites of predilection for cortical and 
deep grey matter injury in early PPMS, for the first time. We developed a voxel-
based technique which demonstrated that regions of localized MTR reduction were 
more widespread than regions of atrophy, but that significant atrophy was not 
present in the absence of MTR reduction. The focus of future work in this area will 
be on expanding our understanding of the processes evolving in this compartment 
over time, in terms of location, quantity and quality. We will apply voxel-based 
techniques longitudinally, to investigate the following questions: (1) Do potentially Understanding progression in PPMS: Conclusions and Future Directions     155 
reversible changes, reflected by MTR reduction, precede irreversible changes, 
reflected by tissue atrophy?  To answer this question, it will be necessary to 
develop a technique which ensures accurate longitudinal intra-subject registration, 
but allows the detection of subtle changes in tissue MTR and volume over time (2) 
Are differences in early symptom prevalence between disease subtypes explained 
by different areas of cortical predilection? This will be investigated by comparing 
patients with early PPMS and early RRMS (3) Do longitudinal changes in specific 
localized areas of damage correlate more closely with clinical progression? If 
progression is found to be associated with damage in specific areas, it may help to 
explain the wide inter-subject variation in clinical course.  
In order for this information to be fully exploited, better understanding of the 
pathological basis of grey matter MTR changes is needed. Post mortem studies 
combining imaging and histopathology are the best way to explore this further 
(Schmierer 2004), although the advanced disease duration of post mortem cases 
limits the relevance of these findings for early PPMS. In vivo, more specific 
analysis of the  macromolecular proton pool is now possible using quantitative MT 
indices, which allow assessment of myelin content without the confounding T1 
effects inherent in MTR measurements (Schmierer 2007). This may elucidate 
whether the grey matter changes we identified are primarily attributable to cortical 
demyelination. Our studies could be further enhanced by incorporating 3D double 
inversion recovery (DIR) sequences, which greatly improve cortical lesion 
detection, and may allow the segmentation of cortical lesions from relatively normal 
appearing areas of grey matter (Geurts 2008).  
Finally, spectroscopic imaging allows the direct measurement of metabolites which 
act as markers for pathological processes. Comparing and combining 
spectroscopic and MTR measures within our cohort may help us to understand the 
balance between demyelination, axonal loss and gliosis  occurring within the grey 
matter areas where MTR is reduced. In addition, combining these techniques with 
atrophy, T2 and T1 lesion measures within one cohort could guide us as to the Understanding progression in PPMS: Conclusions and Future Directions     156 
most useful MRI parameters, or combinations of parameters, for studying clinical 
progression (Mainero 2001). 
Cognition 
In assessing the impact of grey matter injury on progression, our studies have 
focussed on measures of physical disability. However, grey matter changes are 
likely to play a pivotal role in cognitive decline in MS, as evidenced by recent case 
reports describing a purely cortical form of MS, presenting with neurobehavioural 
symptoms (Zarei 2006). We would like to extend our studies to examine the 
relationship between MRI changes in our cohort and cognitive function, specifically 
whether  grey matter parameters at baseline, or the gradient of their decline over 
three years, can determine cognitive outcomes.  
Understanding White matter injury 
Although the work presented in this thesis emphasizes the role of grey matter 
injury in progression, white matter injury was important early on in the study, and 
clearly maintained some influence on long term outcome. Recent studies have 
suggested that the position of white matter lesions may have an influence on 
clinical outcomes independent of lesion burden, and may vary between disease 
subtypes (Di Perri 2008). This would be an interesting area to explore in our 
cohort, as variation in lesion position may explain some of the wide inter-individual 
variability in outcome. Qualitative assessment of lesions using a combination of T1 
and T2-weighted imaging with MTR may also provide a more comprehensive 
picture of the way in which pathological heterogeneity within white matter lesions 
affects disability (Fisher 2007). Damage to specific white matter tracts outside of 
lesions can be studied using tractography; given that we have identified areas of 
predilection for cortical damage, it would be fascinating to examine the white 
matter tracts directly associated with these areas, for example the cortico-spinal 
tracts. In addition, areas of NAWM damage can now be identified in the absence of 
an a priori hypothesis, using tract based spatial statistics (TBSS), which directly Understanding progression in PPMS: Conclusions and Future Directions     157 
complements our localization of grey matter damage using VBM.  Combining grey 
and white matter techniques in this way would allow us to explore the longitudinal 
relationship between damage in the two compartments in PPMS.  Understanding progression in PPMS: Conclusions and Future Directions     158 
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